Loading...

Matthew Cooperberg, MD, MPH

Title(s)Professor, Urology
SchoolSchool of Medicine
Address550 16th. Street
San Francisco CA 94158
Phone415-353-7171
ORCID ORCID Icon0000-0003-4339-6685 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Dartmouth CollegeB.A.1995English
    Yale UniversityM.D.2000Medicine
    Yale UniversityM.P.H.2000Health Policy
    UCSF2008Resident, Urology
    UCSF2009Fellow, Urologic oncology

    Collapse Overview 
    Collapse Overview
    Health Services

    Both clinician and patient decisions influence the choices about the type of treatment a patient will receive for localized prostate and kidney (renal) cancer. Matthew Cooperberg, MD, MPH is conducting an ongoing research program to study national prostate cancer management trends, based on data from CaPSURE and other sources. His analyses have looked at changes in cancer risk over time, testing and treatment for prostate cancer, local variation in treatment, and the impact of socio-demographic factors on type of treatment and outcomes. Through the creation of a San Francisco General Hospital (SFGH) prostate cancer patient registry, preliminary analysis show that low socioeconomic status patients are treated for a higher percentage of high-risk disease than patients with a higher socioeconomic status. Using data from CaPSURE, the NCDB, SFGH and in collaboration with the Urologic Diseases in America project he continues to explore these topic in depth.


    Prostate Cancer Risk Assessment and Comparative Effectiveness Research

    Properly treating prostate cancer requires determining how likely is it that the cancer will progress. Cooperberg led the team that developed the UCSF-CAPRA score, a prostate cancer risk assessment tool that has been validated in several multi-institutional studies in the U.S. and Europe. CAPRA predicts biochemical recurrence-free survival (PSA level does not rise) after radical prostatectomy with an accuracy at least as good as more mathematically complex nomograms that require complex tables or computer software to calculate and other risk assessment instruments. The score is easy to calculate, and can be used to predict an individual's likelihood of metastasis, cancer-specific mortality, and overall mortality after treatment by surgery, radiation therapy, or androgen deprivation therapy.

    Cooperberg is currently developing a post-operative extension of the CAPRA score (CAPRA-S). After surgery additional information is available from the pathologist's analysis of the removed prostate. This information can help identify men who will benefit from additional therapy such as radiation and/or hormonal therapy after surgery. CAPRA-S will help in that decision making process. Cooperberg is also collaborating with a group of Japanese scientist to develop a prediction instrument specifically applicable to high-risk patients and patients receiving androgen deprivation therapy (J-CAPRA). As new biomarkers, such as genomic and advanced imaging data, are proven valid by UCSF Urology and collaborating laboratory investigators, Cooperberg plans to integrate the information into the current standard measures of risk and outcomes to improve risk assessment. These findings will help men determine with greater confidence whether active surveillance, surgery, radiation, hormonal therapy, or some combination may be most appropriate for them.

    Because accurate risk assessment is essential to compare the effectiveness of different prostate cancer treatments, Cooperberg is currently conducting such comparison studies using CaPSURE data. These data will provide a unique source of insight for future comparative effectiveness research.


    Survivorship

    Cooperberg is collaborating on a project that will lead to better clinical care for cancer survivors. His efforts have helped to develop UCSF’s Urologic Oncology Database (UODB) into a comprehensive data repository for clinical information about patients treated for prostate, bladder, and renal cancers. With the Urology Department’s information experts Cooperberg is developing an automated process to further augment UODB by automatically transferring data from the UCSF Medical Center’s information system into UODB. In collaboration with UCSF Breast Oncology and a health care web services company Cooperberg is developing an electronic survey for cancer patients. Patients will complete a health history and health-related quality of life (HRQOL) survey prior to their first visit to the clinic and at defined intervals after treatment. This effort is expected to help patients and clinicians track HRQOL outcomes, such as urinary and sexual function, after treatment. The survey will help physicians to identify those patients who may need to be seen in clinic more or less frequently.


    Small Renal Masses

    In collaboration with the laboratory of John Kurhanewicz, PhD, Cooperberg is conducting a study to see if magnetic resonance spectroscopy (MRS) can be used to non-invasively diagnosis small renal tumors. MRS is a specialized technique associated with magnetic resonance imaging (MRI). MRS equipment can be used to pick up signals from different chemical nuclei within the body. A preliminary laboratory study is using tissue to identify the specific MRS signals associated with a variety of renal tumors. Once renal tumor signals have been identified, Cooperberg plans to test the ability of MRS to accurately analyze renal tumors in patients. This will be done by using MRS imaging technology on patients who are already scheduled for renal cancer surgery prior to their operation. The pre and post surgery information can be analyzed to determine if the information collected non-invasively by the MRS technology matches the histology and grade of the actual tumor.

    Collapse Research 
    Collapse Research Activities and Funding
    Improving Prostate Cancer Outcome Prediction Through Noninvasive exRNA Assessment
    NIH/NCI R01CA198145Aug 10, 2016 - Jul 31, 2021
    Role: Principal Investigator
    Prospective validation of a multi-marker prostate cancer prediction model
    NIH/NCI R01CA160816Aug 8, 2012 - May 31, 2016
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Assessing the Quality of Surgical Care for Clinically Localized Prostate Cancer: Results from the CEASAR Study. J Urol. 2020 Jun 22; 101097JU0000000000001198. Reisz PA, Laviana AA, Zhao Z, Huang LC, Koyama T, Conwill R, Hoffman K, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA. PMID: 32568605.
      View in: PubMed   Mentions:    Fields:    
    2. Risk Factors for Biopsy Reclassification over Time in Men on Active Surveillance for Early Stage Prostate Cancer. J Urol. 2020 Jun 10; 101097JU0000000000001186. Lonergan PE, Washington SL, Cowan JE, Zhao S, Nguyen HG, Shinohara K, Cooperberg MR, Carroll PR. PMID: 32519915.
      View in: PubMed   Mentions:    Fields:    
    3. Obesity, race, and long-term prostate cancer outcomes. Cancer. 2020 Jun 04. Vidal AC, Oyekunle T, Howard LE, De Hoedt AM, Kane CJ, Terris MK, Cooperberg MR, Amling CL, Klaassen Z, Freedland SJ, Aronson WJ. PMID: 32497282.
      View in: PubMed   Mentions:    Fields:    
    4. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. Eur Urol. 2020 May 07. Vickers A, Carlsson SV, Cooperberg M. PMID: 32389443.
      View in: PubMed   Mentions:    Fields:    
    5. Expression of ACE2, the SARS-CoV-2 Receptor, and TMPRSS2 in Prostate Epithelial Cells. Eur Urol. 2020 May 06. Song H, Seddighzadeh B, Cooperberg MR, Huang FW. PMID: 32418620.
      View in: PubMed   Mentions:    Fields:    
    6. Race does not predict skeletal-related events and all-cause mortality in men with castration-resistant prostate cancer. Cancer. 2020 May 06. Patel DN, Howard LE, De Hoedt AM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Klaassen ZW, Terris MK, Freedland SJ. PMID: 32374476.
      View in: PubMed   Mentions:    Fields:    
    7. Magnetic Resonance Imaging for the Detection of High-Grade Cancer in the Canary Prostate Active Surveillance Study. J Urol. 2020 Apr 28; 101097JU0000000000001088. Liss MA, Newcomb LF, Zheng Y, Garcia MP, Filson CP, Boyer H, Brooks JD, Carroll PR, Cooperberg MR, Ellis WJ, Gleave ME, Martin FM, Morgan T, Nelson PS, Wagner AA, Thompson IM, Lin DW. PMID: 32343189.
      View in: PubMed   Mentions:    Fields:    
    8. Expression of ACE2, the SARS-CoV-2 receptor, and TMPRSS2 in prostate epithelial cells. bioRxiv. 2020 Apr 25. Song H, Seddighzadeh B, Cooperberg MR, Huang FW. PMID: 32510524.
      View in: PubMed   Mentions:
    9. Traditional and Virtual Congress Meetings During the COVID-19 Pandemic and the Post-COVID-19 Era: Is it Time to Change the Paradigm? Eur Urol. 2020 Apr 15. Porpiglia F, Checcucci E, Autorino R, Amparore D, Cooperberg MR, Ficarra V, Novara G. PMID: 32334884.
      View in: PubMed   Mentions: 1     Fields:    
    10. Intermediate-risk Prostate Cancer: Stratification and Management. Eur Urol Oncol. 2020 Jun; 3(3):270-280. Preisser F, Cooperberg MR, Crook J, Feng F, Graefen M, Karakiewicz PI, Klotz L, Montironi R, Nguyen PL, D'Amico AV. PMID: 32303478.
      View in: PubMed   Mentions:    Fields:    
    11. Active Surveillance for Prostate Cancer: A 2020 Vision. Eur Urol. 2020 Jun; 77(6):687-688. Cooperberg MR, Lin DW. PMID: 32284244.
      View in: PubMed   Mentions:    Fields:    
    12. Competing Risks of Mortality among Men with Biochemical Recurrence after Radical Prostatectomy. J Urol. 2020 Apr 03; 101097JU0000000000001036. Daskivich TJ, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Klaassen Z, Terris MK, Freedland SJ. PMID: 32243242.
      View in: PubMed   Mentions:    Fields:    
    13. Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data. Cancer. 2020 Jun 15; 126(12):2935-2937. Higano CS, Armstrong AJ, Sartor O, Vogelzang NJ, Kantoff PW, McLeod DG, Pieczonka CM, Penson DF, Shore ND, Vacirca J, Concepcion RS, Tutrone RF, Nordquist LT, Quinn DI, Kassabian V, Scholz MC, Harmon M, Tyler RC, Chang NN, Tang H, Cooperberg MR. PMID: 32154908.
      View in: PubMed   Mentions:    Fields:    
    14. Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. Prostate Cancer Prostatic Dis. 2020 Feb 28. Sartor O, Armstrong AJ, Ahaghotu C, McLeod DG, Cooperberg MR, Penson DF, Kantoff PW, Vogelzang NJ, Hussain A, Pieczonka CM, Shore ND, Quinn DI, Small EJ, Heath EI, Tutrone RF, Schellhammer PF, Harmon M, Chang NN, Sheikh NA, Brown B, Freedland SJ, Higano CS. PMID: 32111923.
      View in: PubMed   Mentions:    Fields:    
    15. Development and Internal Validation of a Web-based Tool to Predict Sexual, Urinary, and Bowel Function Longitudinally After Radiation Therapy, Surgery, or Observation. Eur Urol. 2020 Feb 22. Laviana AA, Zhao Z, Huang LC, Koyama T, Conwill R, Hoffman K, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA. PMID: 32098731.
      View in: PubMed   Mentions:    Fields:    
    16. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). Eur Urol. 2020 Feb 21. Wilt TJ, Vo TN, Langsetmo L, Dahm P, Wheeler T, Aronson WJ, Cooperberg MR, Taylor BC, Brawer MK. PMID: 32089359.
      View in: PubMed   Mentions: 2     Fields:    
    17. The New Surveillance, Epidemiology, and End Results Prostate with Watchful Waiting Database: Opportunities and Limitations. Eur Urol. 2020 Jan 21. Jeong CW, Washington SL, Herlemann A, Gomez SL, Carroll PR, Cooperberg MR. PMID: 31980309.
      View in: PubMed   Mentions:    Fields:    
    18. Reply by Authors. J Urol. 2020 04; 203(4):733. Schenk JM, Newcomb LF, Zheng Y, Faino AV, Zhu K, Nyame YA, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW. PMID: 31951502.
      View in: PubMed   Mentions:    Fields:    
    19. Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. JAMA. 2020 01 14; 323(2):149-163. Hoffman KE, Penson DF, Zhao Z, Huang LC, Conwill R, Laviana AA, Joyce DD, Luckenbaugh AN, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Koyama T, Barocas DA. PMID: 31935027.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    20. Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High-risk Prostate Carcinoma: A Phase III Randomized Study. Eur Urol. 2020 May; 77(5):563-572. Lin DW, Shih MC, Aronson W, Basler J, Beer TM, Brophy M, Cooperberg M, Garzotto M, Kelly WK, Lee K, McGuire V, Wang Y, Lu Y, Markle V, Nseyo U, Ringer R, Savage SJ, Sinnott P, Uchio E, Yang CC, Montgomery RB. PMID: 31924316.
      View in: PubMed   Mentions:    Fields:    
    21. Development and pilot evaluation of a personalized decision support intervention for low risk prostate cancer patients. Cancer Med. 2020 01; 9(1):125-132. Belkora J, Chan JM, Cooperberg MR, Neuhaus J, Stupar L, Weinberg T, Broering JM, Tenggara I, Cowan JE, Rosenfeld S, Kenfield SA, Van Blarigan EL, Simko JP, Witte J, Carroll PR. PMID: 31714037.
      View in: PubMed   Mentions:    Fields:    
    22. Understanding the Major Factors Affecting Response Shift Effects on Health-Related Quality of Life: What the Then-Test Measures in a Longitudinal Prostate Cancer Registry. Clin Genitourin Cancer. 2020 Feb; 18(1):e21-e27. Ten Ham RMT, Broering JM, Cooperberg MR, Carroll P, Wilson LS. PMID: 31796344.
      View in: PubMed   Mentions:    Fields:    
    23. Active surveillance for intermediate-risk prostate cancer: yes, but for whom? Curr Opin Urol. 2019 11; 29(6):605-611. Overland MR, Washington SL, Carroll PR, Cooperberg MR, Herlemann A. PMID: 31436567.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    24. African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study. J Urol. 2020 04; 203(4):727-733. Schenk JM, Newcomb LF, Zheng Y, Faino AV, Zhu K, Nyame YA, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW. PMID: 31651227.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    25. Reply by Authors. J Urol. 2020 01; 203(1):127. Dambal S, Howard LE, Allott EH, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ. PMID: 31609668.
      View in: PubMed   Mentions:    Fields:    
    26. Identification and Characterization of Circulating Tumor Cells in Men Who have Undergone Prostatectomy for Clinically Localized, High Risk Prostate Cancer. J Urol. 2019 10; 202(4):732-741. Friedlander TW, Welty C, Anantharaman A, Schonhoft JD, Jendrisak A, Lee J, Li P, Hough J, Stromlund A, Edwards M, Sangar S, Kobayashi Y, Simko J, Farrokhian N, Lindquist K, Greene S, Ontiveros P, Graf R, Rodriquez A, Suraneni M, Wang Y, Landers M, Carroll P, Cooperberg MR, Dittamore R, Paris PL. PMID: 31216253.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    27. Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance for Early Stage Prostate Cancer. J Urol. 2019 10; 202(4):696-701. Cedars BE, Washington SL, Cowan JE, Leapman M, Tenggara I, Chan JM, Cooperberg MR, Carroll PR. PMID: 30958742.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    28. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance. J Urol. 2019 10; 202(4):702-709. Kornberg Z, Cooperberg MR, Cowan JE, Chan JM, Shinohara K, Simko JP, Tenggara I, Carroll PR. PMID: 31026214.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    29. Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. Cancer. 2019 12 01; 125(23):4172-4180. Higano CS, Armstrong AJ, Sartor AO, Vogelzang NJ, Kantoff PW, McLeod DG, Pieczonka CM, Penson DF, Shore ND, Vacirca J, Concepcion RS, Tutrone RF, Nordquist LT, Quinn DI, Kassabian V, Scholz MC, Harmon M, Tyler RC, Chang NN, Tang H, Cooperberg MR. PMID: 31483485.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    30. Racial Discrepancies in Overall Survival among Men Treated with 223Radium. J Urol. 2020 02; 203(2):331-337. Zhao H, Howard LE, De Hoedt A, Terris MK, Amling CL, Kane CJ, Cooperberg MR, Aronson WJ, Klaassen Z, Polascik TJ, Vidal AC, Freedland SJ. PMID: 31479407.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    31. Obesity at Diagnosis and Prostate Cancer Prognosis and Recurrence Risk Following Primary Treatment by Radical Prostatectomy. Cancer Epidemiol Biomarkers Prev. 2019 11; 28(11):1917-1925. Langlais CS, Cowan JE, Neuhaus J, Kenfield SA, Van Blarigan EL, Broering JM, Cooperberg MR, Carroll P, Chan JM. PMID: 31462398.
      View in: PubMed   Mentions:    Fields:    
    32. Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. Prostate Cancer Prostatic Dis. 2020 03; 23(1):136-143. Herlemann A, Huang HC, Alam R, Tosoian JJ, Kim HL, Klein EA, Simko JP, Chan JM, Lane BR, Davis JW, Davicioni E, Feng FY, McCue P, Kim H, Den RB, Bismar TA, Carroll PR, Cooperberg MR. PMID: 31455846.
      View in: PubMed   Mentions:    Fields:    
    33. Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database. J Urol. 2020 01; 203(1):120-127. Dambal S, Howard LE, Allott EH, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ. PMID: 31430247.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    34. Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance. J Urol. 2019 09; 202(3):506-510. Balakrishnan AS, Cowan JE, Cooperberg MR, Shinohara K, Nguyen HG, Carroll PR. PMID: 30958738.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    35. Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer. 2019 11 15; 125(22):4003-4010. Tablazon IL, Howard LE, De Hoedt AM, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ, Williams SB. PMID: 31390061.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    36. Robust Health Utility Assessment Among Long-term Survivors of Prostate Cancer: Results from the Cancer of the Prostate Strategic Urologic Research Endeavor Registry. Eur Urol. 2019 12; 76(6):743-751. Jeong CW, Cowan JE, Broering JM, Ten Ham RMT, Wilson LS, Carroll PR, Cooperberg MR. PMID: 31345635.
      View in: PubMed   Mentions:    Fields:    
    37. Prostate cancer screening in low- and middle-income countries: the Mexican case. Salud Publica Mex. 2019 Jul-Aug; 61(4):542-544. Lajous M, Cooperberg MR, Rider J, Manzanilla-García HA, Gabilondo-Navarro FB, Rodríguez-Covarrubias FT, López-Ridaura R, Torres-Sánchez LE, Mohar A. PMID: 31314214.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    38. Automating the Capture of Structured Pathology Data for Prostate Cancer Clinical Care and Research. JCO Clin Cancer Inform. 2019 07; 3:1-8. Odisho AY, Bridge M, Webb M, Ameli N, Eapen RS, Stauf F, Cowan JE, Washington SL, Herlemann A, Carroll PR, Cooperberg MR. PMID: 31314550.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    39. Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. JAMA Oncol. 2019 07 01; 5(7):975-983. Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, Amling CL, Aronson WJ, Kane CJ, Terris MK, Zumsteg ZS, Butler S, Osborne JR, Morgan TM, Mehra R, Salami SS, Kishan AU, Wang C, Schaeffer EM, Roach M, Pisansky TM, Shipley WU, Freedland SJ, Sandler HM, Halabi S, Feng FY, Dignam JJ, Nguyen PL, Schipper MJ, Spratt DE. PMID: 31120534.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    40. Interpretation of Domain Scores on the EPIC-How Does the Domain Score Translate into Functional Outcomes? J Urol. 2019 12; 202(6):1150-1158. Laviana AA, Hernandez A, Huang LC, Zhao Z, Koyama T, Conwill R, Hoffman K, Feurer ID, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA. PMID: 31216252.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    41. Trends and Predictors of Adjuvant Therapy for Adverse Features Following Radical Prostatectomy: An Analysis From Cancer of the Prostate Strategic Urologic Research Endeavor. Urology. 2019 Sep; 131:157-165. Balakrishnan AS, Zhao S, Cowan JE, Broering JM, Cooperberg MR, Carroll PR. PMID: 31150694.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    42. Salvage Radiotherapy for Recurrent Prostate Cancer: Can the Prognostic Grade Group System Inform Treatment Timing? Clin Genitourin Cancer. 2019 10; 17(5):e930-e938. Tay KJ, Polascik TJ, Howard LE, Salama JK, Schulman AA, Chen Z, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ. PMID: 31257075.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    43. The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. Eur Urol. 2019 Sep; 76(3):268-272. Cooperberg MR, Carroll PR, Dall'Era MA, Davies BJ, Davis JW, Eggener SE, Feng FY, Lin DW, Morgan TM, Morgans AK, Spratt DE, Taneja SS, Penson DF. PMID: 31128968.
      View in: PubMed   Mentions: 1     Fields:    
    44. Association Between Twitter Reception at a National Urology Conference and Future Publication Status. Eur Urol Focus. 2019 May 15. Nolte AC, Nguyen KA, Perecman A, Katz MS, Kenney PA, Cooperberg MR, Gross CP, Leapman MS. PMID: 31103604.
      View in: PubMed   Mentions:    Fields:    
    45. Influence of African American race on the association between preoperative biopsy grade group and adverse histopathologic features of radical prostatectomy. Cancer. 2019 09 01; 125(17):3025-3032. Aminsharifi A, Schulman A, Howard LE, Tay KJ, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ, Polascik TJ. PMID: 31042315.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    46. Poorly controlled diabetes increases the risk of metastases and castration-resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH database. Cancer. 2019 08 15; 125(16):2861-2867. Nik-Ahd F, Howard LE, Eisenberg AT, Aronson WJ, Terris MK, Cooperberg MR, Amling CL, Kane CJ, Freedland SJ. PMID: 31034601.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    47. Validity of the National Death Index to ascertain the date and cause of death in men having undergone prostatectomy for prostate cancer. Prostate Cancer Prostatic Dis. 2019 12; 22(4):633-635. Moghanaki D, Howard LE, De Hoedt A, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ. PMID: 31036926.
      View in: PubMed   Mentions:    Fields:    
    48. Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. Int J Radiat Oncol Biol Phys. 2019 07 15; 104(4):778-789. Jackson WC, Silva J, Hartman HE, Dess RT, Kishan AU, Beeler WH, Gharzai LA, Jaworski EM, Mehra R, Hearn JWD, Morgan TM, Salami SS, Cooperberg MR, Mahal BA, Soni PD, Kaffenberger S, Nguyen PL, Desai N, Feng FY, Zumsteg ZS, Spratt DE. PMID: 30959121.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    49. The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. J Natl Cancer Inst. 2019 03 01; 111(3):301-310. Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, Sjöström M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Speers C, Nguyen PL, Ross AE, Chan JM, Cooperberg MR, Carroll PR, Davicioni E, Fong L, Spratt DE, Feng FY. PMID: 30321406.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    50. High-throughput, Efficient, and Unbiased Capture of Small RNAs from Low-input Samples for Sequencing. Sci Rep. 2019 02 19; 9(1):2262. Belair CD, Hu T, Chu B, Freimer JW, Cooperberg MR, Blelloch RH. PMID: 30783180.
      View in: PubMed   Mentions: 1     Fields:    
    51. Genomic Prostate Score, PI-RADS™ version 2 and Progression in Men with Prostate Cancer on Active Surveillance. J Urol. 2019 02; 201(2):300-307. Kornberg Z, Cowan JE, Westphalen AC, Cooperberg MR, Chan JM, Zhao S, Shinohara K, Carroll PR. PMID: 30179620.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    52. First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH. Cancer Causes Control. 2019 Mar; 30(3):259-269. Griffin K, Csizmadi I, Howard LE, Pomann GM, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Beebe-Dimmer J, Freedland SJ. PMID: 30701374.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    53. Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project. World J Urol. 2019 Oct; 37(10):2147-2153. van Luijtelaar A, Greenwood BM, Ahmed HU, Barqawi AB, Barret E, Bomers JGR, Brausi MA, Choyke PL, Cooperberg MR, Eggener S, Feller JF, Frauscher F, George AK, Hindley RG, Jenniskens SFM, Klotz L, Kovacs G, Lindner U, Loeb S, Margolis DJ, Marks LS, May S, Mcclure TD, Montironi R, Nour SG, Oto A, Polascik TJ, Rastinehad AR, De Reyke TM, Reijnen JS, de la Rosette JJMCH, Sedelaar JPM, Sperling DS, Walser EM, Ward JF, Villers A, Ghai S, Fütterer JJ. PMID: 30671638.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    54. Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). Prostate Cancer Prostatic Dis. 2019 09; 22(3):438-445. Newcomb LF, Zheng Y, Faino AV, Bianchi-Frias D, Cooperberg MR, Brown MD, Brooks JD, Dash A, Fabrizio MD, Gleave ME, Liss M, Morgan TM, Thompson IM, Wagner AA, Carroll PR, Nelson PS, Lin DW. PMID: 30664734.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    55. Practice patterns and outcomes of equivocal bone scans for patients with castration-resistant prostate cancer: Results from SEARCH. Asian J Urol. 2019 Jul; 6(3):242-248. Hanyok BT, Everist MM, Howard LE, De Hoedt AM, Aronson WJ, Cooperberg MR, Kane CJ, Amling CL, Terris MK, Freedland SJ. PMID: 31297315.
      View in: PubMed   Mentions:
    56. Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer. Eur Urol Oncol. 2019 11; 2(6):685-690. Xu MJ, Kornberg Z, Gadzinski AJ, Diao D, Cowan JE, Wu SY, Boreta L, Spratt DE, Behr SC, Nguyen HG, Cooperberg MR, Davicioni E, Roach M, Hope TA, Carroll PR, Feng FY. PMID: 31411984.
      View in: PubMed   Mentions:    Fields:    
    57. Feasibility, Acceptability, and Behavioral Outcomes from a Technology-enhanced Behavioral Change Intervention (Prostate 8): A Pilot Randomized Controlled Trial in Men with Prostate Cancer. Eur Urol. 2019 06; 75(6):950-958. Kenfield SA, Van Blarigan EL, Ameli N, Lavaki E, Cedars B, Paciorek AT, Monroy C, Tantum LK, Newton RU, Signorell C, Suh JH, Zhang L, Cooperberg MR, Carroll PR, Chan JM. PMID: 30638635.
      View in: PubMed   Mentions: 2     Fields:    
    58. Socioeconomic status, race, and long-term outcomes after radical prostatectomy in an equal access health system: Results from the SEARCH database. Urol Oncol. 2019 04; 37(4):289.e11-289.e17. Everist MM, Howard LE, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ. PMID: 30598238.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    59. Health Care Delivery for Metastatic Hormone-sensitive Prostate Cancer Across the Globe. Eur Urol Focus. 2019 03; 5(2):155-158. Herlemann A, Washington SL, Cooperberg MR. PMID: 30587443.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    60. Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer. J Nucl Med. 2019 07; 60(7):910-916. Behr SC, Aggarwal R, VanBrocklin HF, Flavell RR, Gao K, Small EJ, Blecha J, Jivan S, Hope TA, Simko JP, Kurhanewicz J, Noworolski SM, Korn NJ, De Los Santos R, Cooperberg MR, Carroll PR, Nguyen HG, Greene KL, Langton-Webster B, Berkman CE, Seo Y. PMID: 30464040.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    61. Obesity, risk of biochemical recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. BJU Int. 2019 07; 124(1):69-75. Freedland SJ, Branche BL, Howard LE, Hamilton RJ, Aronson WJ, Terris MK, Cooperberg MR, Amling CL, Kane CJ. PMID: 30347135.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    62. Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy? Cancer. 2019 02 01; 125(3):434-441. Vidal AC, Howard LE, De Hoedt A, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Lechpammer S, Flanders SC, Freedland SJ. PMID: 30427535.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    63. PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics. World J Urol. 2019 Jul; 37(7):1255-1261. Eapen RS, Nzenza TC, Murphy DG, Hofman MS, Cooperberg M, Lawrentschuk N. PMID: 30374609.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    64. Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database. Clin Genitourin Cancer. 2019 Feb; 17(1):e140-e149. Aminsharifi A, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Polascik TJ, Freedland SJ. PMID: 30366879.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    65. Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2019 05; 22(2):252-260. Whitney CA, Howard LE, Freedland SJ, DeHoedt AM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Daskivich TJ. PMID: 30279582.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    66. Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital. Int J Urol. 2018 12; 25(12):998-1004. Patel DN, Jha S, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Chapin BF, Freedland SJ. PMID: 30253446.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    67. ESTIMATING AND COMPARING CANCER PROGRESSION RISKS UNDER VARYING SURVEILLANCE PROTOCOLS. Ann Appl Stat. 2018 Sep; 12(3):1773-1795. Lange JM, Gulati R, Leonardson AS, Lin DW, Newcomb LF, Trock BJ, Carter HB, Cooperberg MR, Cowan JE, Klotz LH, Etzioni R. PMID: 30627300.
      View in: PubMed   Mentions:
    68. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy. Eur Urol. 2018 11; 74(5):668-675. Leapman MS, Nguyen HG, Cowan JE, Xue L, Stohr B, Simko J, Cooperberg MR, Carroll PR. PMID: 30181067.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    69. Contemporary prostate cancer radiation therapy in the United States: Patterns of care and compliance with quality measures. Pract Radiat Oncol. 2018 Sep - Oct; 8(5):307-316. Lee DJ, Barocas DA, Zhao Z, Huang LC, Koyama T, Resnick MJ, Conwill R, McCollum D, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hashibe M, Kaplan SH, Paddock LE, Stroup AM, Wu XC, Penson DF, Hoffman KE. PMID: 30177030.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    70. Online Professionalism-2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media. Eur Urol. 2018 11; 74(5):644-650. Borgmann H, Cooperberg M, Murphy D, Loeb S, N'Dow J, Ribal MJ, Woo H, Rouprêt M, Winterbottom A, Wijburg C, Wirth M, Catto J, Kutikov A. PMID: 30177286.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    71. Practice patterns of primary EBRT with and without ADT in prostate cancer treatment. Prostate Cancer Prostatic Dis. 2019 03; 22(1):117-124. Schmidt B, Eapen RS, Cowan JE, Broering JM, Greene KL, Carroll PR, Cooperberg MR. PMID: 30171230.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    72. Measuring quality of urology care using a qualified clinical data registry. Curr Opin Urol. 2018 07; 28(4):329-335. Gadzinski AJ, Cooperberg MR. PMID: 29847522.
      View in: PubMed   Mentions:    Fields:    
    73. Report of the third Asian Prostate Cancer study meeting. Prostate Int. 2019 Jun; 7(2):60-67. Lojanapiwat B, Lee JY, Gang Z, Kim CS, Fai NC, Hakim L, Umbas R, Ong TA, Lim J, Letran JL, Chiong E, Lee SH, Türkeri L, Murphy DG, Moretti K, Cooperberg M, Carlile R, Hinotsu S, Hirao Y, Kitamura T, Horie S, Onozawa M, Kitagawa Y, Namiki M, Fukagai T, Miyazaki J, Akaza H. PMID: 31384607.
      View in: PubMed   Mentions:
    74. Genomic biomarkers in prostate cancer. Transl Androl Urol. 2018 Jun; 7(3):459-471. Kornberg Z, Cooperberg MR, Spratt DE, Feng FY. PMID: 30050804.
      View in: PubMed   Mentions:
    75. Comparison of Patient-reported Outcomes After External Beam Radiation Therapy and Combined External Beam With Low-dose-rate Brachytherapy Boost in Men With Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018 09 01; 102(1):116-126. Lee DJ, Barocas DA, Zhao Z, Huang LC, Resnick MJ, Koyoma T, Conwill R, McCollum D, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hashibe M, Kaplan SH, Paddock LE, Stroup AM, Wu XC, Penson DF, Hoffman KE. PMID: 30102188.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    76. The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer. Eur Urol. 2018 10; 74(4):444-452. Cooperberg MR, Erho N, Chan JM, Feng FY, Fishbane N, Zhao SG, Simko JP, Cowan JE, Lehrer J, Alshalalfa M, Kolisnik T, Chelliserry J, Margrave J, Aranes M, Plessis MD, Buerki C, Tenggara I, Davicioni E, Carroll PR. PMID: 29853306.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    77. Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer. Eur Urol Oncol. 2018 10; 1(5):386-394. Masic S, Cowan JE, Washington SL, Nguyen HG, Shinohara K, Cooperberg MR, Carroll PR. PMID: 31158077.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    78. A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. Eur Urol. 2018 08; 74(2):197-203. Ankerst DP, Straubinger J, Selig K, Guerrios L, De Hoedt A, Hernandez J, Liss MA, Leach RJ, Freedland SJ, Kattan MW, Nam R, Haese A, Montorsi F, Boorjian SA, Cooperberg MR, Poyet C, Vertosick E, Vickers AJ. PMID: 29778349.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    79. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. Eur Urol Oncol. 2018 05; 1(1):78-82. Aggarwal R, Wei X, Kim W, Small EJ, Ryan CJ, Carroll P, Cooperberg M, Evans MJ, Hope T. PMID: 31100231.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    80. Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes Control. 2018 06; 29(6):581-588. Vidal AC, Howard LE, de Hoedt A, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Taioli E, Fowke JH, Freedland SJ. PMID: 29663110.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    81. Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2018 07; 122(1):76-82. Vidal AC, Howard LE, de Hoedt A, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Freedland SJ. PMID: 29521009.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    82. The Research Implications of Prostate Specific Antigen Registry Errors: Data from the Veterans Health Administration. J Urol. 2018 09; 200(3):541-548. Guo DP, Thomas IC, Mittakanti HR, Shelton JB, Makarov DV, Skolarus TA, Cooperberg MR, Sonn GA, Chung BI, Brooks JD, Leppert JT. PMID: 29630980.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    83. Radical prostatectomy and the effect of close surgical margins: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2018 10; 122(4):592-598. Herforth C, Stroup SP, Chen Z, Howard LE, Freedland SJ, Moreira DM, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ. PMID: 29473992.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    84. How Should a Man with Prostate Cancer Choose his Surgeon? Eur Urol. 2018 06; 73(6):826-827. Cooperberg MR. PMID: 29409668.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    85. Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results. Eur Urol. 2018 07; 74(1):26-33. Tyson MD, Koyama T, Lee D, Hoffman KE, Resnick MJ, Wu XC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hashibe M, Paddock LE, Stroup A, Chen V, Conwill R, McCollum D, Penson DF, Barocas DA. PMID: 29501451.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    86. First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database. Urol Oncol. 2018 May; 36(5):239.e17-239.e25. McDonald ML, Howard LE, Aronson WJ, Terris MK, Cooperberg MR, Amling CL, Freedland SJ, Kane CJ. PMID: 29429895.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    87. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. Eur Urol. 2018 08; 74(2):211-217. Cooperberg MR, Brooks JD, Faino AV, Newcomb LF, Kearns JT, Carroll PR, Dash A, Etzioni R, Fabrizio MD, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Zheng Y. PMID: 29433975.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    88. Prostate Cancer Markers. Cancer Treat Res. 2018; 175:55-86. Gadzinski AJ, Cooperberg MR. PMID: 30168117.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    89. The Effect of Nerve Sparing Status on Sexual and Urinary Function: 3-Year Results from the CEASAR Study. J Urol. 2018 05; 199(5):1202-1209. Avulova S, Zhao Z, Lee D, Huang LC, Koyama T, Hoffman KE, Conwill RM, Wu XC, Chen V, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hashibe M, Paddock LE, Stroup A, Resnick MJ, Penson DF, Barocas DA. PMID: 29253578.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    90. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol. 2018 02 01; 36(4):414-424. Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG. PMID: 29236593.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    91. The use of PET/CT in prostate cancer. Prostate Cancer Prostatic Dis. 2018 04; 21(1):4-21. Li R, Ravizzini GC, Gorin MA, Maurer T, Eiber M, Cooperberg MR, Alemozzaffar M, Tollefson MK, Delacroix SE, Chapin BF. PMID: 29230009.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    92. Declining Incidence Rates of Prostate Cancer in the United States: Is This Good News or Not? JAMA Oncol. 2017 12 01; 3(12):1623-1624. Downer MK, Stampfer MJ, Cooperberg MR. PMID: 28494051.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    93. Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncol. 2017 12 01; 3(12):1663-1672. Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M, Speers C, Cooperberg MR, Kim W, Ryan CJ, Den RB, Freedland SJ, Posadas E, Sandler H, Klein EA, Black P, Seiler R, Tomlins SA, Chinnaiyan AM, Jenkins RB, Davicioni E, Ross AE, Schaeffer EM, Nguyen PL, Carroll PR, Karnes RJ, Spratt DE, Feng FY. PMID: 28494073.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    94. Re: Follow-up of Prostatectomy Versus Observation for Early Prostate Cancer. Eur Urol. 2018 Mar; 73(3):477-478. Cooperberg MR. PMID: 29195775.
      View in: PubMed   Mentions:    Fields:    
    95. Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts. Ann Intern Med. 2018 01 02; 168(1):1-9. Inoue LYT, Lin DW, Newcomb LF, Leonardson AS, Ankerst D, Gulati R, Carter HB, Trock BJ, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Mamedov A, Penson DF, Etzioni R. PMID: 29181514.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    96. Genomic Markers in Prostate Cancer Decision Making. Eur Urol. 2018 04; 73(4):572-582. Cucchiara V, Cooperberg MR, Dall'Era M, Lin DW, Montorsi F, Schalken JA, Evans CP. PMID: 29129398.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    97. Whom to Treat: Postdiagnostic Risk Assessment with Gleason Score, Risk Models, and Genomic Classifier. Urol Clin North Am. 2017 Nov; 44(4):547-555. Herlemann A, Washington SL, Eapen RS, Cooperberg MR. PMID: 29107271.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    98. Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH. Prostate. 2017 Dec; 77(16):1592-1600. Zumsteg ZS, Chen Z, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Spratt DE, Sandler HM, Freedland SJ. PMID: 28994485.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    99. Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa). PLoS One. 2017; 12(10):e0185535. Leapman MS, Westphalen AC, Ameli N, Lawrence HJ, Febbo PG, Cooperberg MR, Carroll PR. PMID: 29016610.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    100. Active Surveillance for Low-Risk Prostate Cancer-An Evolving International Standard of Care. JAMA Oncol. 2017 10 01; 3(10):1398-1399. Cooperberg MR. PMID: 27768167.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    101. Validation of GEMCaP as a DNA Based Biomarker to Predict Prostate Cancer Recurrence after Radical Prostatectomy. J Urol. 2018 03; 199(3):719-725. Nguyen HG, Welty C, Lindquist K, Ngo V, Gilbert E, Bengtsson H, Magi-Galluzzi C, Jean-Gilles J, Yao J, Cooperberg M, Messing E, Klein EA, Carroll PR, Paris PL. PMID: 28941923.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    102. The Cancer of the Bladder Risk Assessment (COBRA) score: Estimating mortality after radical cystectomy. Cancer. 2017 Dec 01; 123(23):4574-4582. Welty CJ, Sanford TH, Wright JL, Carroll PR, Cooperberg MR, Meng MV, Porten SP. PMID: 28881475.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    103. Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group. J Urol. 2018 03; 199(3):713-718. Teeter AE, Griffin K, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ. PMID: 28870860.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    104. Outcomes of men on active surveillance for low-risk prostate cancer at a safety-net hospital. Urol Oncol. 2017 11; 35(11):663.e9-663.e14. Osterberg EC, Palmer NRA, Harris CR, Murphy GP, Blaschko SD, Chu C, Allen IE, Cooperberg MR, Carroll PR, Breyer BN. PMID: 28826701.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    105. Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence. Urology. 2017 Oct; 108:129-134. Skove SL, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Moreira DM, Freedland SJ. PMID: 28735016.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    106. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. Eur Urol. 2018 02; 73(2):156-165. Spratt DE, Dess RT, Zumsteg ZS, Lin DW, Tran PT, Morgan TM, Antonarakis ES, Nguyen PL, Ryan CJ, Sandler HM, Cooperberg MR, Posadas E, Feng FY. PMID: 28716370.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    107. Predictors of operative time during radical retropubic prostatectomy and robot-assisted laparoscopic prostatectomy. Int J Urol. 2017 08; 24(8):618-623. Simon RM, Howard LE, Moreira DM, Terris MK, Kane CJ, Aronson WJ, Amling CL, Cooperberg MR, Freedland SJ. PMID: 28697533.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    108. Biopsy Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis and Mortality in a Cohort of Men with High Risk Prostate Cancer. J Urol. 2017 12; 198(6):1309-1315. Stroup SP, Moreira DM, Chen Z, Howard L, Berger JH, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Freedland SJ. PMID: 28709888.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    109. Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system. Cancer. 2017 Nov 01; 123(21):4122-4129. Schulman AA, Howard LE, Tay KJ, Tsivian E, Sze C, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ, Polascik TJ. PMID: 28662291.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    110. Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database. Cancer. 2017 Nov 01; 123(21):4199-4206. Freedland SJ, Vidal AC, Howard LE, Terris MK, Cooperberg MR, Amling CL, Kane CJ, Aronson WJ. PMID: 28654204.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    111. Characterization of a "low-risk" cohort of grade group 2 prostate cancer patients: Results from the Shared Equal Access Regional Cancer Hospital database. Int J Urol. 2017 08; 24(8):611-617. McGinley KF, Sun X, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ. PMID: 28589550.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    112. The New US Preventive Services Task Force "C" Draft Recommendation for Prostate Cancer Screening. Eur Urol. 2017 09; 72(3):326-328. Cooperberg MR. PMID: 28535948.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    113. Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med. 2017 12; 58(12):1956-1961. Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg MR, Feng F, Chang A, Ryan CJ, Small EJ, Carroll PR. PMID: 28522741.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    114. Epidemiology of prostate cancer. World J Urol. 2017 06; 35(6):849. Cooperberg MR, Chan JM. PMID: 28509969.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    115. Community-based Outcomes of Open versus Robot-assisted Radical Prostatectomy. Eur Urol. 2018 02; 73(2):215-223. Herlemann A, Cowan JE, Carroll PR, Cooperberg MR. PMID: 28499617.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    116. Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging. Curr Opin Urol. 2017 May; 27(3):205-209. Eapen RS, Herlemann A, Washington SL, Cooperberg MR. PMID: 28221220.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansPHPublic Health
    117. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer. BJU Int. 2017 11; 120(5B):E80-E86. Howard LE, Moreira DM, De Hoedt A, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ. PMID: 28371163.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    118. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. 2018 02; 73(2):168-175. Karnes RJ, Choeurng V, Ross AE, Schaeffer EM, Klein EA, Freedland SJ, Erho N, Yousefi K, Takhar M, Davicioni E, Cooperberg MR, Trock BJ. PMID: 28400167.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    119. Report of the Second Asian Prostate Cancer (A-CaP) Study Meeting. Prostate Int. 2017 Sep; 5(3):95-103. Kim CS, Lee JY, Chung BH, Kim WJ, Fai NC, Hakim L, Umbas R, Ong TA, Lim J, Letran JL, Chiong E, Wu TL, Lojanapiwat B, Türkeri L, Murphy DG, Gardiner RA, Moretti K, Cooperberg M, Carroll P, Mun SK, Hinotsu S, Hirao Y, Ozono S, Horie S, Onozawa M, Kitagawa Y, Kitamura T, Namiki M, Akaza H. PMID: 28828352.
      View in: PubMed   Mentions:
    120. Active Surveillance in Younger Men With Prostate Cancer. J Clin Oncol. 2017 Jun 10; 35(17):1898-1904. Leapman MS, Cowan JE, Nguyen HG, Shinohara KK, Perez N, Cooperberg MR, Catalona WJ, Carroll PR. PMID: 28346806.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    121. Interpreting Patient Reported Urinary and Sexual Function Outcomes across Multiple Validated Instruments. J Urol. 2017 09; 198(3):671-677. Vertosick EA, Vickers AJ, Cowan JE, Broering JM, Carroll PR, Cooperberg MR. PMID: 28342935.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    122. Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years. JAMA. 2017 03 21; 317(11):1126-1140. Barocas DA, Alvarez J, Resnick MJ, Koyama T, Hoffman KE, Tyson MD, Conwill R, McCollum D, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hashibe M, Kaplan SH, Paddock LE, Stroup AM, Wu XC, Penson DF. PMID: 28324093.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    123. Clinical risk-stratification for prostate cancer: Where are we, and where do we need to go? Can Urol Assoc J. 2017 Mar-Apr; 11(3-4):101-102. Cooperberg MR. PMID: 28515808.
      View in: PubMed   Mentions:
    124. The Influence of Psychosocial Constructs on the Adherence to Active Surveillance for Localized Prostate Cancer in a Prospective, Population-based Cohort. Urology. 2017 05; 103:173-178. Lang MF, Tyson MD, Alvarez JR, Koyama T, Hoffman KE, Resnick MJ, Cooperberg MR, Wu XC, Chen V, Paddock LE, Hamilton AS, Hashibe M, Goodman M, Greenfield S, Kaplan SH, Stroup A, Penson DF, Barocas DA. PMID: 28189554.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    125. Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer. Cancer. 2017 05 01; 123(9):1528-1535. Klaassen Z, Howard LE, de Hoedt A, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ. PMID: 28026865.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    126. Clinically localized prostate cancer in 2017: A review of comparative effectiveness. Urol Oncol. 2017 02; 35(2):40-41. Lavery HJ, Cooperberg MR. PMID: 27998677.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    127. Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes. Eur Urol. 2017 05; 71(5):750-759. Leapman MS, Cowan JE, Simko J, Roberge G, Stohr BA, Carroll PR, Cooperberg MR. PMID: 27940155.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    128. Tissue Sources for Accurate Measurement of Germline DNA Genotypes in Prostate Cancer Patients Treated With Radical Prostatectomy. Prostate. 2017 03; 77(4):425-434. Emami NC, Leong L, Wan E, Van Blarigan EL, Cooperberg MR, Tenggara I, Carroll PR, Chan JM, Witte JS, Simko JP. PMID: 27900799.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    129. Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study. Eur Urol. 2017 09; 72(3):448-454. Lin DW, Newcomb LF, Brown MD, Sjoberg DD, Dong Y, Brooks JD, Carroll PR, Cooperberg M, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Zheng Y. PMID: 27889277.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    130. Magnetic Resonance Imaging-targeted Prostate Biopsies: Is the Right Technique the Right Question? Eur Urol. 2017 04; 71(4):532-533. Cooperberg MR. PMID: 27839778.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    131. Racial Variation in Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Results from the CEASAR Study. Eur Urol. 2017 08; 72(2):307-314. Tyson MD, Alvarez J, Koyama T, Hoffman KE, Resnick MJ, Wu XC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hashibe M, Paddock LE, Stroup A, Chen VW, Penson DF, Barocas DA. PMID: 27816300.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    132. Re: 10-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. Eur Urol. 2017 03; 71(3):492-493. Cooperberg MR. PMID: 27817968.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    133. What Early ProtecT Results Have Confirmed About Risk-stratified Prostate Cancer Management. Eur Urol. 2017 03; 71(3):389-390. Cooperberg MR. PMID: 27815085.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    134. Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort. Am J Surg Pathol. 2016 11; 40(11):1439-1456. McKenney JK, Wei W, Hawley S, Auman H, Newcomb LF, Boyer HD, Fazli L, Simko J, Hurtado-Coll A, Troyer DA, Tretiakova MS, Vakar-Lopez F, Carroll PR, Cooperberg MR, Gleave ME, Lance RS, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, Brooks JD. PMID: 27635949.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    135. Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. Lancet Oncol. 2016 Nov; 17(11):1612-1620. Zhao SG, Chang SL, Spratt DE, Erho N, Yu M, Ashab HA, Alshalalfa M, Speers C, Tomlins SA, Davicioni E, Dicker AP, Carroll PR, Cooperberg MR, Freedland SJ, Karnes RJ, Ross AE, Schaeffer EM, Den RB, Nguyen PL, Feng FY. PMID: 27743920.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    136. Accuracy of Prostate-Specific Antigen Values in Prostate Cancer Registries. J Clin Oncol. 2016 10 10; 34(29):3586-3587. Mittakanti HR, Thomas IC, Shelton JB, Makarov DV, Skolarus TA, Cooperberg MR, Chung BI, Sonn GA, Brooks JD, Leppert JT. PMID: 27458297.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    137. Obesity and prostate cancer-specific mortality after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Prostate Cancer Prostatic Dis. 2017 03; 20(1):72-78. Vidal AC, Howard LE, Sun SX, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Freedland SJ. PMID: 27698439.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    138. Long-term oncological outcomes of apical positive surgical margins at radical prostatectomy in the Shared Equal Access Regional Cancer Hospital cohort. Prostate Cancer Prostatic Dis. 2016 12; 19(4):423-428. Wadhwa H, Terris MK, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ, Abern MR. PMID: 27698440.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    139. Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. Cancer Immunol Res. 2016 11; 4(11):948-958. Wei XX, Chan S, Kwek S, Lewis J, Dao V, Zhang L, Cooperberg MR, Ryan CJ, Lin AM, Friedlander TW, Rini B, Kane C, Simko JP, Carroll PR, Small EJ, Fong L. PMID: 27688020.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    140. Number of Unfavorable Intermediate-Risk Factors Predicts Pathologic Upstaging and Prostate Cancer-Specific Mortality Following Radical Prostatectomy: Results From the SEARCH Database. Prostate. 2017 02; 77(2):154-163. Zumsteg ZS, Chen Z, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Spratt DE, Sandler HM, Freedland SJ. PMID: 27683213.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    141. A Randomized Study of Intraoperative Autologous Retropubic Urethral Sling on Urinary Control after Robotic Assisted Radical Prostatectomy. J Urol. 2017 02; 197(2):369-375. Nguyen HG, Punnen S, Cowan JE, Leapman M, Cary C, Welty C, Weinberg V, Cooperberg MR, Meng MV, Greene KL, Garcia M, Carroll PR. PMID: 27693447.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    142. The CAPRA Score at 10 Years: Contemporary Perspectives and Analysis of Supporting Studies. Eur Urol. 2017 05; 71(5):705-709. Brajtbord JS, Leapman MS, Cooperberg MR. PMID: 27616723.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    143. Temporal Trends and the Impact of Race, Insurance, and Socioeconomic Status in the Management of Localized Prostate Cancer. Eur Urol. 2017 05; 71(5):729-737. Gray PJ, Lin CC, Cooperberg MR, Jemal A, Efstathiou JA. PMID: 27597241.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    144. Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH. Clin Genitourin Cancer. 2017 02; 15(1):60-66.e2. Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, Pratson CL, Hanyok BT, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Freedland SJ. PMID: 27692812.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    145. In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database. Eur Urol Focus. 2017 10; 3(4-5):480-486. Whitney CA, Howard LE, Posadas EM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ. PMID: 28753787.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    146. Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer. Clin Genitourin Cancer. 2017 06; 15(3):e299-e309. Lobo JM, Trifiletti DM, Sturz VN, Dicker AP, Buerki C, Davicioni E, Cooperberg MR, Karnes RJ, Jenkins RB, Den RB, Showalter TN. PMID: 28089723.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    147. Race does not predict the development of metastases in men with nonmetastatic castration-resistant prostate cancer. Cancer. 2016 Dec 15; 122(24):3848-3855. Whitney CA, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ. PMID: 27505036.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    148. Targeted PET imaging for prostate-specific membrane antigen in prostate cancer. Future Oncol. 2016 Nov; 12(21):2393-2396. Hope TA, Aggarwal RR, Westphalen AC, Cooperberg MR, Greene KL. PMID: 27453303.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    149. Validity of the Cancer of the Prostate Risk Assessment Score Derived From Targeted Biopsy: Modeling Evidence From Ultrasound Lesion-Directed Biopsy. Clin Genitourin Cancer. 2017 02; 15(1):93-99. Leapman MS, Ameli N, Shinohara K, Nguyen HG, Meng MV, Cooperberg MR, Carroll PR. PMID: 27522449.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    150. An Approach Using PSA Levels of 1.5?ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care. Urology. 2016 Oct; 96:116-120. Crawford ED, Rosenberg MT, Partin AW, Cooperberg MR, Maccini M, Loeb S, Pettaway CA, Shore ND, Arangua P, Hoenemeyer J, Leveridge M, Leapman M, Pinto P, Thompson IM, Carroll P, Eastham J, Gomella L, Klein EA. PMID: 27450937.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    151. Prostate cancer: Why the prostate arm of the PLCO trial failed and what it has taught us. Nat Rev Urol. 2016 08; 13(8):439-40. Cooperberg MR. PMID: 27400667.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    152. Preoperative Frailty Is Associated With Discharge to Skilled or Assisted Living Facilities After Urologic Procedures of Varying Complexity. Urology. 2016 11; 97:25-32. Suskind AM, Jin C, Cooperberg MR, Finlayson E, Boscardin WJ, Sen S, Walter LC. PMID: 27392651.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    153. Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer? Prostate Cancer Prostatic Dis. 2016 12; 19(4):380-384. Howard LE, De Hoedt AM, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Divers CH, Valderrama A, Freedland SJ. PMID: 27377207.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    154. Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies. JAMA Oncol. 2016 Jul 01; 2(7):890-8. Roth JA, Gulati R, Gore JL, Cooperberg MR, Etzioni R. PMID: 27010943.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansPHPublic Health
    155. Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy. J Urol. 2016 11; 196(5):1408-1414. Leapman MS, Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Walker K, Amling CL, Carroll PR, Cooperberg MR. PMID: 27352635.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    156. Predictors of Time to Metastasis in Castration-resistant Prostate Cancer. Urology. 2016 Oct; 96:171-176. Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, Hanyok BT, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Liede A, Freedland SJ. PMID: 27318265.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    157. Quantified Clinical Risk Change as an End Point During Prostate Cancer Active Surveillance. Eur Urol. 2017 09; 72(3):329-332. Leapman MS, Ameli N, Cooperberg MR, Chu C, Hussein A, Shinohara K, Carroll PR. PMID: 27157998.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    158. Clinical Utility of Biomarkers in Localized Prostate Cancer. Curr Oncol Rep. 2016 May; 18(5):30. Leapman MS, Nguyen HG, Cooperberg MR. PMID: 27023445.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    159. Asia prostate cancer study (A-CaP Study) launch symposium. Prostate Int. 2016 Sep; 4(3):88-96. Akaza H, Hirao Y, Kim CS, Oya M, Ozono S, Ye D, Cooperberg M, Hinotsu S, Lee JY, Zhu G, Namiki M, Horie S, Chung BH, Chen CH, Fai NC, Hakim L, Chiong E, Letran J, Umbas R, Suzuki K, Nishimura K, Ong TA, Lojanapiwat B, Wu TL, Kim WJ, Murphy D, Ogawa O, Carroll P, Naito S, Tsukamoto T. PMID: 27689065.
      View in: PubMed   Mentions:
    160. Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens. J Mol Diagn. 2016 05; 18(3):395-406. Knudsen BS, Kim HL, Erho N, Shin H, Alshalalfa M, Lam LLC, Tenggara I, Chadwich K, Van Der Kwast T, Fleshner N, Davicioni E, Carroll PR, Cooperberg MR, Chan JM, Simko JP. PMID: 26945428.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    161. When to Start Prostate Cancer Screening and When to Stop: Insights from Göteborg. J Urol. 2016 May; 195(5):1325-1326. Cooperberg M. PMID: 26901508.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    162. Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol. 2016 06 20; 34(18):2182-90. Chen RC, Rumble RB, Loblaw DA, Finelli A, Ehdaie B, Cooperberg MR, Morgan SC, Tyldesley S, Haluschak JJ, Tan W, Justman S, Jain S. PMID: 26884580.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    163. Validation of a bone scan positivity risk table in non-metastatic castration-resistant prostate cancer. BJU Int. 2016 Oct; 118(4):570-7. Freedland SJ, Howard LE, Hanyok BT, Kadiyala VK, Kuang JY, Whitney CA, Wilks FR, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Aronson WJ, Moreira DM. PMID: 26762961.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    164. Words of Wisdom. Re: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma. Eur Urol. 2016 Feb; 69(2):374-5. Tasian GE, Cooperberg MR. PMID: 26758522.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    165. Racial Differences in the Association Between Preoperative Serum Cholesterol and Prostate Cancer Recurrence: Results from the SEARCH Database. Cancer Epidemiol Biomarkers Prev. 2016 Mar; 25(3):547-54. Allott EH, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ. PMID: 26809276.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    166. Variation in prostate cancer treatment associated with population density of the county of residence. Prostate Cancer Prostatic Dis. 2016 06; 19(2):174-9. Cary C, Odisho AY, Cooperberg MR. PMID: 26782713.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    167. Impact of frailty on complications in patients undergoing common urological procedures: a study from the American College of Surgeons National Surgical Quality Improvement database. BJU Int. 2016 May; 117(5):836-42. Suskind AM, Walter LC, Jin C, Boscardin J, Sen S, Cooperberg MR, Finlayson E. PMID: 26691588.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    168. Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate Score. Urology. 2016 Mar; 89:69-75. Brand TC, Zhang N, Crager MR, Maddala T, Dee A, Sesterhenn IA, Simko JP, Cooperberg MR, Srivastava S, Rosner IL, Chan JM, Febbo PG, Carroll PR, Cullen J, Lawrence HJ. PMID: 26723180.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    169. Utilization and impact of surgical technique on the performance of pelvic lymph node dissection at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database. Int J Urol. 2016 Mar; 23(3):241-6. McGinley KF, Sun X, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ. PMID: 26667212.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    170. Treatment Trends for Prostate Cancer--Reply. JAMA. 2015 Nov 10; 314(18):1977-8. Cooperberg MR, Carroll PR. PMID: 26547474.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    171. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database. Cancer. 2016 Jan 15; 122(2):222-9. Hanyok BT, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Posadas EM, Freedland SJ. PMID: 26484853.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    172. Reply from Authors re: Julia Verne, Luke Hounsome, Roger Kockelbergh, Jem Rashbass. Improving Outcomes from Prostate Cancer: Unlocking the Treasure Trove of Information in Cancer Registries. Eur Urol 2016;69:1013-4. Eur Urol. 2016 06; 69(6):1015. Gandaglia G, Bray F, Cooperberg MR, Karnes RJ, Leveridge MJ, Moretti K, Murphy DG, Penson DF, Miller DC. PMID: 26443428.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    173. Do all men with pathological Gleason score 8-10 prostate cancer have poor outcomes? Results from the SEARCH database. BJU Int. 2016 08; 118(2):250-7. Fischer S, Lin D, Simon RM, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ, Vidal AC. PMID: 26351095.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    174. Does larger tumor volume explain the higher prostate specific antigen levels in black men with prostate cancer--Results from the SEARCH database. Cancer Epidemiol. 2015 Dec; 39(6):1066-70. Klaassen Z, Howard L, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Freedland SJ. PMID: 26452418.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    175. The Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples. J Urol. 2016 Feb; 195(2):321-9. O'Neil B, Koyama T, Alvarez J, Conwill RM, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Hoffman RM, Kaplan SH, Stanford JL, Stroup AM, Paddock LE, Wu XC, Stephenson RA, Resnick MJ, Barocas DA, Penson DF. PMID: 26343985.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    176. Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. J Urol. 2016 Feb; 195(2):313-20. Newcomb LF, Thompson IM, Boyer HD, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Ellis WJ, Fazli L, Feng Z, Gleave ME, Kunju P, Lance RS, McKenney JK, Meng MV, Nicolas MM, Sanda MG, Simko J, So A, Tretiakova MS, Troyer DA, True LD, Vakar-Lopez F, Virgin J, Wagner AA, Wei JT, Zheng Y, Nelson PS, Lin DW. PMID: 26327354.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansPHPublic Health
    177. Rebuttal to Drs. Markovina and Michalski. Brachytherapy. 2015 Nov-Dec; 14(6):761-2. Hussein AA, Cooperberg MR. PMID: 26254833.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    178. Point: Surgery is the most cost-effective option for prostate cancer needing treatment. Brachytherapy. 2015 Nov-Dec; 14(6):753-5. Hussein AA, Cooperberg MR. PMID: 26249124.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    179. Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. JAMA. 2015 Jul 07; 314(1):80-2. Cooperberg MR, Carroll PR. PMID: 26151271.
      View in: PubMed   Mentions: 114     Fields:    Translation:Humans
    180. Adverse pathology and undetectable ultrasensitive prostate-specific antigen after radical prostatectomy: is adjuvant radiation warranted? BJU Int. 2016 06; 117(6):897-903. Simon RM, Howard LE, Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Vidal AC. PMID: 26010251.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    181. Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort. BJU Int. 2016 Feb; 117(2):244-8. Mithal P, Howard LE, Aronson WJ, Terris MK, Cooperberg MR, Kane CJ, Amling C, Freedland SJ. PMID: 26010160.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    182. Prostate Cancer Registries: Current Status and Future Directions. Eur Urol. 2016 06; 69(6):998-1012. Gandaglia G, Bray F, Cooperberg MR, Karnes RJ, Leveridge MJ, Moretti K, Murphy DG, Penson DF, Miller DC. PMID: 26056070.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    183. Editorial Comment. Urology. 2015 Jun; 85(6):1223. Cooperberg MR. PMID: 26099866.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    184. Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2015 Dec; 18(4):333-7. Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, Hanyok BT, Pratson CL, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Liede A, Freedland SJ. PMID: 26171882.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    185. Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter? BJU Int. 2015 Nov; 116(5):713-20. Hsu CC, Paciorek AT, Cooperberg MR, Roach M, Hsu IC, Carroll PR. PMID: 25600860.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    186. Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. Eur Urol. 2016 05; 69(5):775-87. Bayne CE, Williams SB, Cooperberg MR, Gleave ME, Graefen M, Montorsi F, Novara G, Smaldone MC, Sooriakumaran P, Wiklund PN, Chapin BF. PMID: 26003223.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    187. Agent Orange and long-term outcomes after radical prostatectomy. Urol Oncol. 2015 Jul; 33(7):329.e1-6. Ovadia AE, Terris MK, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ, Abern MR. PMID: 25998746.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    188. Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer. BJU Int. 2016 Jan; 117(1):102-9. Cooperberg MR, Hinotsu S, Namiki M, Carroll PR, Akaza H. PMID: 25238114.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    189. Genomic Predictors of Outcome in Prostate Cancer. Eur Urol. 2015 Dec; 68(6):1033-44. Boström PJ, Bjartell AS, Catto JW, Eggener SE, Lilja H, Loeb S, Schalken J, Schlomm T, Cooperberg MR. PMID: 25913390.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    190. Smoking is a predictor of adverse pathological features at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database. Int J Urol. 2015 Jul; 22(7):658-62. Zapata DF, Howard LE, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Freedland SJ. PMID: 25872110.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    191. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study. Eur J Cancer. 2015 May; 51(7):817-24. Garcia-Albeniz X, Chan JM, Paciorek A, Logan RW, Kenfield SA, Cooperberg MR, Carroll PR, Hernán MA. PMID: 25794605.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    192. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database. Int J Urol. 2015 Apr; 22(4):362-6. Mithal P, Howard LE, Aronson WJ, Kane CJ, Cooperberg MR, Terris MK, Amling CL, Freedland SJ. PMID: 25728968.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    193. Nationally representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America project. Prostate Cancer Prostatic Dis. 2015 Jun; 18(2):149-54. Cary KC, Punnen S, Odisho AY, Litwin MS, Saigal CS, Cooperberg MR. PMID: 25667110.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    194. Impact of age on quality-of-life outcomes after treatment for localized prostate cancer. Eur Urol. 2015 Sep; 68(3):480-6. Hampson LA, Cowan JE, Zhao S, Carroll PR, Cooperberg MR. PMID: 25656807.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    195. Proton therapy websites: information anarchy creates confusion. BJU Int. 2015 Feb; 115(2):183-5. Basto M, Cooperberg MR, Murphy DG. PMID: 25756133.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    196. Current Use of Imaging after Primary Treatment of Prostate Cancer. J Urol. 2015 Jul; 194(1):98-104. Hussein AA, Punnen S, Zhao S, Cowan JE, Leapman M, Tran TC, Washington SL, Truesdale MD, Carroll PR, Cooperberg MR. PMID: 25640648.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    197. Who bears the greatest burden of aggressive treatment of indolent prostate cancer? Am J Med. 2015 Jun; 128(6):609-16. Mahal BA, Cooperberg MR, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Orio PF, Trinh QD, Nguyen PL. PMID: 25644324.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    198. Diagnostic associations of gene expression signatures in prostate cancer tissue. Curr Opin Urol. 2015 Jan; 25(1):65-70. Nguyen HG, Welty CJ, Cooperberg MR. PMID: 25405934.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    199. Long-term active surveillance for prostate cancer: answers and questions. J Clin Oncol. 2015 Jan 20; 33(3):238-40. Cooperberg MR. PMID: 25512464.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansPHPublic Health
    200. Is clinical stage T2c prostate cancer an intermediate- or high-risk disease? Cancer. 2015 May 01; 121(9):1414-21. Klaassen Z, Singh AA, Howard LE, Feng Z, Trock B, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Partin A, Han M, Freedland SJ. PMID: 25492369.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    201. Practice patterns and predictors of followup imaging after a negative bone scan in men with castration resistant prostate cancer: results from the SEARCH database. J Urol. 2015 Apr; 193(4):1232-8. Sourbeer KN, Howard LE, Moreira DM, Amarasekara HS, Chow LD, Cockrell DC, Hanyok BT, Pratson CL, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Hernandez RK, Freedland SJ. PMID: 25463986.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    202. Sustainable Measurement of Response Shift in Prostate Cancer Patients: Adjusting Health Related Quality of Life with the Then-Test. Value Health. 2014 Nov; 17(7):A651. Ten Ham RM, Wilson LS, Broering JM, Cooperberg MR, Carroll P. PMID: 27202352.
      View in: PubMed   Mentions:    Fields:    
    203. Overdetection of recurrence after radical prostatectomy: estimates based on patient and tumor characteristics. Clin Cancer Res. 2014 Oct 15; 20(20):5302-10. Xia J, Trock BJ, Gulati R, Mallinger L, Cooperberg MR, Carroll PR, Carter HB, Etzioni R. PMID: 25320374.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    204. Serum lipid profile and risk of prostate cancer recurrence: Results from the SEARCH database. Cancer Epidemiol Biomarkers Prev. 2014 Nov; 23(11):2349-56. Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Freedland SJ. PMID: 25304929.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    205. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer. J Urol. 2015 Mar; 193(3):807-11. Welty CJ, Cowan JE, Nguyen H, Shinohara K, Perez N, Greene KL, Chan JM, Meng MV, Simko JP, Cooperberg MR, Carroll PR. PMID: 25261803.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    206. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry. Eur Urol. 2015 Oct; 68(4):600-8. Punnen S, Cowan JE, Chan JM, Carroll PR, Cooperberg MR. PMID: 25242555.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    207. Progress in management of low-risk prostate cancer: how registries may change the world. Eur Urol. 2015 Jan; 67(1):51-52. Cooperberg MR. PMID: 25242556.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    208. A simple schema for informed decision making about prostate cancer screening. Ann Intern Med. 2014 Sep 16; 161(6):441-2. Vickers AJ, Edwards K, Cooperberg MR, Mushlin AI. PMID: 25222389.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    209. The Evolution of Self-Reported Urinary and Sexual Dysfunction over the Last Two Decades: Implications for Comparative Effectiveness Research. Eur Urol. 2015 Jun; 67(6):1019-1025. Resnick MJ, Barocas DA, Morgans AK, Phillips SE, Koyama T, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Hoffman RM, Kaplan SH, McCollum D, Paddock LE, Stanford JL, Stroup AM, Wu XC, Penson DF. PMID: 25174325.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    210. European Urology: serving our readership through systematic peer review, use of reporting standards, and encouragement of postpublication review. Eur Urol. 2015 Feb; 67(2):188-90. Catto JW, Cooperberg MR, Cornu JN, Gratzke C, Novara G, Shariat SF, Vickers A. PMID: 25175422.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    211. Reply to Yuri Tolkach, Markus Kuczyk, Florian Imkamp's letter to the editor re: Eric A. Klein, Matthew R. Cooperberg, Cristina Magi-Galluzzi, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur urol 2014;66:550-60. Eur Urol. 2014 Dec; 66(6):e117-8. Klein EA, Cooperberg MR, Carroll PR. PMID: 25150174.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    212. Expected population impacts of discontinued prostate-specific antigen screening. Cancer. 2014 Nov 15; 120(22):3519-26. Gulati R, Tsodikov A, Etzioni R, Hunter-Merrill RA, Gore JL, Mariotto AB, Cooperberg MR. PMID: 25065910.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    213. European Association of Urology (@Uroweb) recommendations on the appropriate use of social media. Eur Urol. 2014 Oct; 66(4):628-32. Rouprêt M, Morgan TM, Bostrom PJ, Cooperberg MR, Kutikov A, Linton KD, Palou J, Martínez-Piñeiro L, van der Poel H, Wijburg C, Winterbottom A, Woo HH, Wirth MP, Catto JW. PMID: 25043941.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    214. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol. 2015 Feb; 67(2):326-33. Cooperberg MR, Davicioni E, Crisan A, Jenkins RB, Ghadessi M, Karnes RJ. PMID: 24998118.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    215. Implications of the new AUA guidelines on prostate cancer detection in the U.S. Curr Urol Rep. 2014 Jul; 15(7):420. Cooperberg MR. PMID: 24844775.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    216. Seventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management. Prostate Int. 2014; 2(2):50-69. Akaza H, Kim CS, Carroll P, Choi IY, Chung BH, Cooperberg MR, Hirao Y, Hinotsu S, Horie S, Lee JY, Namiki M, Ng CF, Onozawa M, Ozono S, Ueno S, Umbas R, Ye D, Zhu G. PMID: 26153555.
      View in: PubMed   Mentions:
    217. miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance. PLoS One. 2014; 9(6):e98597. Wang SY, Shiboski S, Belair CD, Cooperberg MR, Simko JP, Stoppler H, Cowan J, Carroll PR, Blelloch R. PMID: 24893170.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    218. Use of social media in urology: data from the American Urological Association (AUA). BJU Int. 2014 Jun; 113(6):993-8. Loeb S, Bayne CE, Frey C, Davies BJ, Averch TD, Woo HH, Stork B, Cooperberg MR, Eggener SE. PMID: 24274744.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    219. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol. 2014 Sep; 66(3):550-60. Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner FL, Knezevic D, Febbo PG, Shak S, Kattan MW, Lee M, Carroll PR. PMID: 24836057.
      View in: PubMed   Mentions: 124     Fields:    Translation:HumansCells
    220. Updated trends in imaging use in men diagnosed with prostate cancer. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):246-51. Porten SP, Smith A, Odisho AY, Litwin MS, Saigal CS, Carroll PR, Cooperberg MR. PMID: 24819235.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    221. Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2014 Nov; 114(5):661-6. Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Freedland SJ. PMID: 24588774.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    222. Meaningful end points and outcomes in men on active surveillance for early-stage prostate cancer. Curr Opin Urol. 2014 May; 24(3):288-92. Welty CJ, Cooperberg MR, Carroll PR. PMID: 24614347.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    223. Racial variation in prostate cancer upgrading and upstaging among men with low-risk clinical characteristics. Eur Urol. 2015 Mar; 67(3):451-7. Jalloh M, Myers F, Cowan JE, Carroll PR, Cooperberg MR. PMID: 24746973.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    224. Prostate cancer: a new look at prostate cancer treatment complications. Nat Rev Clin Oncol. 2014 Jun; 11(6):304-5. Cooperberg MR. PMID: 24687033.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    225. Editorial comment. J Urol. 2014 Jul; 192(1):80-1. Cooperberg MR. PMID: 24703980.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    226. The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer. Cancer. 2014 Jun 01; 120(11):1656-62. Abern MR, Terris MK, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ. PMID: 24647966.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    227. Early detection of prostate cancer. Urol Clin North Am. 2014 May; 41(2):xiii. Loeb S, Cooperberg MR. PMID: 24725496.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    228. A risk-adjusted definition of biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis. 2014 Jun; 17(2):174-9. Morgan TM, Meng MV, Cooperberg MR, Cowan JE, Weinberg V, Carroll PR, Lin DW. PMID: 24614692.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    229. Limited ability of existing nomograms to predict outcomes in men undergoing active surveillance for prostate cancer. BJU Int. 2014 Dec; 114(6b):E18-E24. Wang SY, Cowan JE, Cary KC, Chan JM, Carroll PR, Cooperberg MR. PMID: 24712895.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    230. Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: Defining the population at risk for harms of prostate cancer treatment. Cancer. 2014 Apr 15; 120(8):1263-71. Resnick MJ, Barocas DA, Morgans AK, Phillips SE, Chen VW, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Kaplan SH, Paddock LE, Stroup AM, Wu XC, Koyama T, Penson DF. PMID: 24510400.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    231. The Melbourne Consensus Statement on the early detection of prostate cancer. BJU Int. 2014 Feb; 113(2):186-8. Murphy DG, Ahlering T, Catalona WJ, Crowe H, Crowe J, Clarke N, Cooperberg M, Gillatt D, Gleave M, Loeb S, Roobol M, Sartor O, Pickles T, Wootten A, Walsh PC, Costello AJ. PMID: 24206066.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansPHPublic Health
    232. Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review. Eur Urol. 2014 Jun; 65(6):1023-31. van den Bergh RC, Ahmed HU, Bangma CH, Cooperberg MR, Villers A, Parker CC. PMID: 24491309.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    233. Predicting bone scan positivity after biochemical recurrence following radical prostatectomy in both hormone-naive men and patients receiving androgen-deprivation therapy: results from the SEARCH database. Prostate Cancer Prostatic Dis. 2014 Mar; 17(1):91-6. Moreira DM, Cooperberg MR, Howard LE, Aronson WJ, Kane CJ, Terris MK, Amling CL, Kuchibhatla M, Freedland SJ. PMID: 24418913.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    234. Implementation of PSA-based active surveillance in prostate cancer. Biomark Med. 2014; 8(5):747-53. Jalloh M, Cooperberg MR. PMID: 25123041.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    235. Impact of national guidelines on brachytherapy monotherapy practice patterns for prostate cancer. Cancer. 2014 Mar 15; 120(6):824-32. Tseng YD, Paciorek AT, Martin NE, D'Amico AV, Cooperberg MR, Nguyen PL. PMID: 24301555.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    236. Biomarkers in prostate cancer surveillance and screening: past, present, and future. Ther Adv Urol. 2013 Dec; 5(6):318-29. Cary KC, Cooperberg MR. PMID: 24294290.
      View in: PubMed   Mentions:
    237. Impact of androgen deprivation therapy on mental and emotional well-being in men with prostate cancer: analysis from the CaPSURE™ registry. J Urol. 2014 Apr; 191(4):964-70. Cary KC, Singla N, Cowan JE, Carroll PR, Cooperberg MR. PMID: 24184370.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    238. Temporal trends and predictors of salvage cancer treatment after failure following radical prostatectomy or radiation therapy: an analysis from the CaPSURE registry. Cancer. 2014 Feb 15; 120(4):507-12. Cary KC, Paciorek A, Fuldeore MJ, Carroll PR, Cooperberg MR. PMID: 24496867.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    239. Long-term follow-up of International Prostate Symptom Score (IPSS) in men following prostate brachytherapy. World J Urol. 2014 Aug; 32(4):1061-6. Li X, Fang D, Cooperberg MR, Whitson JM, Lue TF, Zhou L, Shinohara K. PMID: 24141807.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    240. Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database. Cancer. 2014 Jan 15; 120(2):197-204. Moreira DM, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Boffetta P, Freedland SJ. PMID: 24127391.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    241. Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. Prostate Cancer Prostatic Dis. 2013 Dec; 16(4):391-7. Allott EH, Abern MR, Gerber L, Keto CJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Moorman PG, Freedland SJ. PMID: 24100644.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    242. Reply to A. Azad et al. J Clin Oncol. 2013 Sep 10; 31(26):3296-7. Cooperberg MR, Cowan JE, Carroll PR. PMID: 23943835.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    243. Re-examining racial disparities in prostate cancer outcomes. J Clin Oncol. 2013 Aug 20; 31(24):2979-80. Cooperberg MR. PMID: 23878300.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    244. Divorcing diagnosis from treatment: contemporary management of low-risk prostate cancer. Korean J Urol. 2013 Jul; 54(7):417-25. Glass AS, Punnen S, Cooperberg MR. PMID: 23878682.
      View in: PubMed   Mentions: 2     Fields:    
    245. Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study. J Comp Eff Res. 2013 Jul; 2(4):445-60. Barocas DA, Chen V, Cooperberg M, Goodman M, Graff JJ, Greenfield S, Hamilton A, Hoffman K, Kaplan S, Koyama T, Morgans A, Paddock LE, Phillips S, Resnick MJ, Stroup A, Wu XC, Penson DF. PMID: 24236685.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    246. The epidemiology of high-risk prostate cancer. Curr Opin Urol. 2013 Jul; 23(4):331-6. Punnen S, Cooperberg MR. PMID: 23619582.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansPHPublic Health
    247. A longitudinal study of anxiety, depression and distress as predictors of sexual and urinary quality of life in men with prostate cancer. BJU Int. 2013 Jul; 112(2):E67-75. Punnen S, Cowan JE, Dunn LB, Shumay DM, Carroll PR, Cooperberg MR. PMID: 23795800.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    248. Expanding utilization of intensity-modulated radiotherapy for prostate cancer: soaring costs, dubious benefits: comment on "Comparative effectiveness of intensity-modulated radiotherapy and conventional conformal radiotherapy in the treatment of prostate cancer after radical prostatectomy". JAMA Intern Med. 2013 Jun 24; 173(12):1143-4. Cooperberg MR. PMID: 23689487.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    249. Words of wisdom. Re: Quality-of-life effects of prostate-specific antigen screening. Eur Urol. 2013 Jun; 63(6):1130. Cooperberg MR. PMID: 23608080.
      View in: PubMed   Mentions:    Fields:    
    250. Risk-based prostate cancer screening: who and how? Curr Urol Rep. 2013 Jun; 14(3):192-8. Glass AS, Cary KC, Cooperberg MR. PMID: 23532499.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic Health
    251. Sixth joint meeting of J-CaP and CaPSURE--a multinational perspective on prostate cancer management and patient outcomes. Jpn J Clin Oncol. 2013 Jul; 43(7):756-66. Akaza H, Hinotsu S, Cooperberg MR, Chung BH, Youl Lee J, Umbas R, Tsukamoto T, Namiki M, Carroll P. PMID: 23723314.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    252. Patient demographics, quality of life, and disease features of men with newly diagnosed prostate cancer: trends in the PSA era. Urology. 2013 Jul; 82(1):60-5. Glass AS, Cowan JE, Fuldeore MJ, Cooperberg MR, Carroll PR, Kenfield SA, Greene KL. PMID: 23706257.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    253. Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2013 Dec; 64(6):905-15. Punnen S, Cooperberg MR, D'Amico AV, Karakiewicz PI, Moul JW, Scher HI, Schlomm T, Freedland SJ. PMID: 23721958.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    254. Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy. Eur Urol. 2014 Jun; 65(6):1171-7. Punnen S, Freedland SJ, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Carroll PR, Cooperberg MR. PMID: 23587869.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    255. Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening. Med Care. 2013 Apr; 51(4):295-300. Etzioni R, Gulati R, Cooperberg MR, Penson DM, Weiss NS, Thompson IM. PMID: 23269114.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    256. How does robot-assisted radical prostatectomy (RARP) compare with open surgery in men with high-risk prostate cancer? BJU Int. 2013 Aug; 112(4):E314-20. Punnen S, Meng MV, Cooperberg MR, Greene KL, Cowan JE, Carroll PR. PMID: 23451984.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    257. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol. 2013 Apr 10; 31(11):1428-34. Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnagar S, Gutin A, Lanchbury JS, Swanson GP, Stone S, Carroll PR. PMID: 23460710.
      View in: PubMed   Mentions: 87     Fields:    Translation:Humans
    258. Proximal bulbar periurethral abscess. Int Braz J Urol. 2013 Jan-Feb; 39(1):137-8. Blaschko SD, Weiss DA, Odisho AY, Greene KL, Cooperberg MR. PMID: 23489506.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    259. Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis. BJU Int. 2013 Mar; 111(3):437-50. Cooperberg MR, Ramakrishna NR, Duff SB, Hughes KE, Sadownik S, Smith JA, Tewari AK. PMID: 23279038.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    260. Role of active surveillance in the management of localized prostate cancer. J Natl Cancer Inst Monogr. 2012 Dec; 2012(45):202-6. Glass AS, Cooperberg MR, Meng MV, Carroll PR. PMID: 23271774.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    261. Factors associated with treatment received by men diagnosed with prostate cancer in queensland, australia. BJU Int. 2012 Dec; 110(11 Pt B):E720. Cooperberg MR. PMID: 23017189.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    262. Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res. 2012 Oct 01; 18(19):5471-8. Xia J, Trock BJ, Cooperberg MR, Gulati R, Zeliadt SB, Gore JL, Lin DW, Carroll PR, Carter HB, Etzioni R. PMID: 23008476.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    263. High-risk nonmuscle invasive bladder cancer: definition and epidemiology. Curr Opin Urol. 2012 Sep; 22(5):385-9. Porten SP, Cooperberg MR. PMID: 22842681.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    264. Reply to Jai Prakash, Apul Goel and Manish Garg's Letter to the Editor re: Anobel Y. Odisho, Anna B. Berry, Ardalan E. Ahmad, Matthew R. Cooperberg, Peter R. Carroll, Badrinath R. Konety. Reflex ImmunoCyt Testing for the Diagnosis of Bladder Cancer in Patients with Atypical Urine Cytology. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.04.019. Eur Urol. 2012 Nov; 62(5):e88. Odisho AY, Berry AB, Ahmad AE, Cooperberg MR, Carroll PR, Konety BR. PMID: 22921716.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    265. Prostate cancer: new types of radiotherapy improve cancer outcome but at what cost? Nat Rev Urol. 2012 Aug; 9(8):415-7. Murphy DG, Williams S, Cooperberg MR. PMID: 22750953.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    266. Early detection of prostate cancer: more information, more clarity. Eur Urol. 2012 Nov; 62(5):753-5; discussion 755-6. Glass AS, Cooperberg MR, Carroll PR. PMID: 22766168.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    267. Editorial comment. Urology. 2012 Aug; 80(2):305-6. Cooperberg MR, Chan JM. PMID: 22749427.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    268. Will biomarkers save prostate cancer screening? Eur Urol. 2012 Dec; 62(6):962-3; discussion 964-5. Cooperberg MR. PMID: 22749734.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    269. Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogram. Prostate Cancer Prostatic Dis. 2012 Dec; 15(4):374-9. Kutikov A, Cooperberg MR, Paciorek AT, Uzzo RG, Carroll PR, Boorjian SA. PMID: 22710832.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    270. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol. 2012 Dec; 62(6):976-83. Dall'Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C, Soloway MS. PMID: 22698574.
      View in: PubMed   Mentions: 132     Fields:    Translation:Humans
    271. The quantitative Gleason score improves prostate cancer risk assessment. Cancer. 2012 Dec 15; 118(24):6046-54. Reese AC, Cowan JE, Brajtbord JS, Harris CR, Carroll PR, Cooperberg MR. PMID: 22674220.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    272. Urological cancer: For localized prostate cancer, does technology equal progress? Nat Rev Clin Oncol. 2012 Jun 05; 9(7):371-2. Cooperberg MR. PMID: 22665365.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    273. To predict the future, consider the present as well as the past. Eur Urol. 2012 Jul; 62(1):53-4. Cooperberg MR. PMID: 22521092.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    274. Reflex ImmunoCyt testing for the diagnosis of bladder cancer in patients with atypical urine cytology. Eur Urol. 2013 May; 63(5):936-40. Odisho AY, Berry AB, Ahmad AE, Cooperberg MR, Carroll PR, Konety BR. PMID: 22521093.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    275. Thwarting high-risk prostate cancer: the right treatments for the right patients. Eur Urol. 2012 Jun; 61(6):1107-9. Cooperberg MR. PMID: 22475772.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    276. Proton beam therapy and treatment for localized prostate cancer: if you build it, they will come. Arch Intern Med. 2012 Feb 13; 172(3):280-3. Aaronson DS, Odisho AY, Hills N, Cress R, Carroll PR, Dudley RA, Cooperberg MR. PMID: 22332166.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    277. Fifth Joint Meeting of J-CaP and CaPSURE: advancing the global understanding of prostate cancer and its management. Jpn J Clin Oncol. 2012 Mar; 42(3):226-36. Akaza H, Carroll P, Cooperberg MR, Hinotsu S. PMID: 22217576.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    278. Outcomes for radical prostatectomy: is it the singer, the song, or both? J Clin Oncol. 2012 Feb 10; 30(5):476-8. Cooperberg MR, Odisho AY, Carroll PR. PMID: 22215744.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    279. Adverse effects of androgen deprivation and the limits of national tumor registries. Eur Urol. 2012 Apr; 61(4):701-3; discussion 703-4. Cooperberg MR. PMID: 22176779.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    280. PSA screening: determinants of primary-care physician practice patterns. Prostate Cancer Prostatic Dis. 2012 Jun; 15(2):189-94. Tasian GE, Cooperberg MR, Potter MB, Cowan JE, Greene KL, Carroll PR, Chan JM. PMID: 22343837.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansPHPublic Health
    281. High-risk prostate cancer: treat the prostate. Lancet. 2011 Dec 17; 378(9809):2056-7. Cooperberg MR. PMID: 22056154.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    282. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):100-5. Wu AK, Reese AC, Cooperberg MR, Sadetsky N, Shinohara K. PMID: 22042252.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    283. External-beam radiation therapy should be given with androgen deprivation treatment for intermediate-risk prostate cancer: new confirmatory evidence. Asian J Androl. 2012 Jan; 14(1):132-3. Cooperberg MR. PMID: 22036804.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    284. Among potent men post radical prostatectomy, does the need for phosphodiesterase inhibitors have an impact on sexual bother scores? BJU Int. 2012 May; 109(10):1520-4. Punnen S, Cooperberg MR, Sadetsky N, Carroll PR. PMID: 21999368.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    285. Words of wisdom. Re: Radical prostatectomy versus watchful waiting in early prostate cancer. Eur Urol. 2011 Oct; 60(4):868-9. Cooperberg MR. PMID: 21878196.
      View in: PubMed   Mentions:    Fields:    
    286. Prediction of erectile function following treatment for prostate cancer. JAMA. 2011 Sep 21; 306(11):1205-14. Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, Hembroff L, Sadetsky N, Saigal CS, Litwin MS, Klein E, Kibel AS, Hamstra DA, Pisters LL, Kuban DA, Kaplan ID, Wood DP, Ciezki J, Dunn RL, Carroll PR, Sanda MG. PMID: 21934053.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansPHPublic Health
    287. Androgen deprivation therapy and cardiovascular risk. J Clin Oncol. 2011 Sep 10; 29(26):3510-6. Punnen S, Cooperberg MR, Sadetsky N, Carroll PR. PMID: 21844498.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    288. Active surveillance for prostate cancer: progress and promise. J Clin Oncol. 2011 Sep 20; 29(27):3669-76. Cooperberg MR, Carroll PR, Klotz L. PMID: 21825257.
      View in: PubMed   Mentions: 90     Fields:    Translation:HumansPHPublic Health
    289. Treatment trends for stage I renal cell carcinoma. J Urol. 2011 Aug; 186(2):394-9. Cooperberg MR, Mallin K, Kane CJ, Carroll PR. PMID: 21679982.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    290. The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer. 2011 Nov 15; 117(22):5039-46. Cooperberg MR, Hilton JF, Carroll PR. PMID: 21647869.
      View in: PubMed   Mentions: 65     Fields:    Translation:Humans
    291. Editorial comment. Urology. 2011 Jun; 77(6):1336-7. Cooperberg MR. PMID: 21624594.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    292. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol. 2011 Jul 10; 29(20):2795-800. Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K, Perez N, Greene KL, Meng MV, Carroll PR. PMID: 21632511.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    293. Factors associated with downgrading in patients with high grade prostate cancer. Urol Oncol. 2013 May; 31(4):442-7. Whitson JM, Porten SP, Cowan JE, Simko JP, Cooperberg MR, Carroll PR. PMID: 21478037.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    294. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol. 2011 May; 185(5):1656-60. Whitson JM, Porten SP, Hilton JF, Cowan JE, Perez N, Cooperberg MR, Greene KL, Meng MV, Simko JP, Shinohara K, Carroll PR. PMID: 21419438.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansPHPublic Health
    295. Impact of androgen deprivation on physical well-being in patients with prostate cancer: analysis from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry. Cancer. 2011 Oct 01; 117(19):4406-13. Sadetsky N, Greene K, Cooperberg MR, Hubbard A, Carroll PR, Satariano W. PMID: 21412760.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    296. The example of CaPSURE: lessons learned from a national disease registry. World J Urol. 2011 Jun; 29(3):265-71. Porten SP, Cooperberg MR, Konety BR, Carroll PR. PMID: 21347810.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    297. Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes? J Clin Oncol. 2011 Feb 01; 29(4):345-7. Carroll PR, Whitson JM, Cooperberg MR. PMID: 21189396.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansPHPublic Health
    298. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol. 2011 Jan 10; 29(2):235-41. Bechis SK, Carroll PR, Cooperberg MR. PMID: 21135285.
      View in: PubMed   Mentions: 70     Fields:    Translation:Humans
    299. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol. 2011 Jan 10; 29(2):228-34. Cooperberg MR, Cowan JE, Hilton JF, Reese AC, Zaid HB, Porten SP, Shinohara K, Meng MV, Greene KL, Carroll PR. PMID: 21115873.
      View in: PubMed   Mentions: 67     Fields:    Translation:Humans
    300. Inaccuracies in assignment of clinical stage for localized prostate cancer. Cancer. 2011 Jan 15; 117(2):283-9. Reese AC, Sadetsky N, Carroll PR, Cooperberg MR. PMID: 21210472.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    301. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer. 2010 Nov 15; 116(22):5226-34. Cooperberg MR, Vickers AJ, Broering JM, Carroll PR. PMID: 20690197.
      View in: PubMed   Mentions: 83     Fields:    Translation:Humans
    302. Disproportionate presentation of high risk prostate cancer in a safety net health system. J Urol. 2010 Nov; 184(5):1931-6. Porten SP, Richardson DA, Odisho AY, McAninch JW, Carroll PR, Cooperberg MR. PMID: 20846693.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    303. Prostate specific antigen screening for prostate cancer: knowledge of, attitudes towards, and utilization among primary care physicians. Urol Oncol. 2012 Mar-Apr; 30(2):155-60. Tasian GE, Cooperberg MR, Cowan JE, Keyashian K, Greene KL, Daniels NA, Carroll PR, Chan JM. PMID: 20800514.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansPHPublic Health
    304. Gender differences in subcutaneous and perirenal fat distribution. Surg Radiol Anat. 2010 Nov; 32(9):879-82. Eisner BH, Zargooshi J, Berger AD, Cooperberg MR, Doyle SM, Sheth S, Stoller ML. PMID: 20607260.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    305. Adequacy of a single 24-hour urine collection for metabolic evaluation of recurrent nephrolithiasis. J Urol. 2010 Aug; 184(2):579-83. Castle SM, Cooperberg MR, Sadetsky N, Eisner BH, Stoller ML. PMID: 20639021.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    306. Electronic patient self-assessment and management (SAM): a novel framework for cancer survivorship. BMC Med Inform Decis Mak. 2010 Jun 17; 10:34. Vickers AJ, Salz T, Basch E, Cooperberg MR, Carroll PR, Tighe F, Eastham J, Rosen RC. PMID: 20565745.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    307. Specialist visits (urologist, radiation oncologist, medical oncologist) are strongly associated with treatment received for prostate cancer in the USA. Evid Based Med. 2010 Jun; 15(3):95-6. Cooperberg MR. PMID: 20522696.
      View in: PubMed   Mentions: 1     Fields:    
    308. Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease. J Urol. 2010 Jul; 184(1):114-9. Reese AC, Cooperberg MR, Carroll PR. PMID: 20478578.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    309. Urologist density and county-level urologic cancer mortality. J Clin Oncol. 2010 May 20; 28(15):2499-504. Odisho AY, Cooperberg MR, Fradet V, Ahmad AE, Carroll PR. PMID: 20406931.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    310. Changes in specific domains of sexual function and sexual bother after radical prostatectomy. BJU Int. 2010 Oct; 106(7):1022-9. Le JD, Cooperberg MR, Sadetsky N, Hittelman AB, Meng MV, Cowan JE, Latini DM, Carroll PR. PMID: 20184571.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    311. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010 Mar 01; 28(7):1117-23. Cooperberg MR, Broering JM, Carroll PR. PMID: 20124165.
      View in: PubMed   Mentions: 279     Fields:    Translation:Humans
    312. In vivo tumor grading of prostate cancer using quantitative 111In-capromab pendetide SPECT/CT. J Nucl Med. 2010 Jan; 51(1):31-6. Seo Y, Aparici CM, Cooperberg MR, Konety BR, Hawkins RA. PMID: 20008977.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    313. The independent value of tumour volume in a contemporary cohort of men treated with radical prostatectomy for clinically localized disease. BJU Int. 2010 Feb; 105(4):472-5. Porten SP, Cooperberg MR, Carroll PR. PMID: 19681901.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    314. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol. 2009 Sep 10; 27(26):4306-13. Cooperberg MR, Hinotsu S, Namiki M, Ito K, Broering J, Carroll PR, Akaza H. PMID: 19667269.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    315. Fourth joint meeting of the American Urological Association and the Japanese Urological Association Specialty Society program at the 104th annual meeting of the American Urological Association at Chicago 2009. Int J Urol. 2009 Aug; 16(8):703-8. Cooperberg MR, Hinotsu S, Chancellor MB, Homma Y, Nelson PS, Matsuyama H, Menon M, Kucuk O, Hara I, Egawa S, Uzzo RG, Kanayama HO, Okuyama A, Akaza H. PMID: 19682110.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    316. Prostate-cancer screening. N Engl J Med. 2009 Jul 09; 361(2):203; author reply 204-5. Cooperberg MR, Carroll PR. PMID: 19593852.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic Health
    317. Defining high quality health care. Urol Oncol. 2009 Jul-Aug; 27(4):411-6. Cooperberg MR, Birkmeyer JD, Litwin MS. PMID: 19573771.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    318. Candidate quality of care indicators for localized bladder cancer. Urol Oncol. 2009 Jul-Aug; 27(4):435-42. Cooperberg MR, Porter MP, Konety BR. PMID: 19573775.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    319. Adequacy of lymphadenectomy among men undergoing robot-assisted laparoscopic radical prostatectomy. BJU Int. 2010 Jan; 105(1):88-92. Cooperberg MR, Kane CJ, Cowan JE, Carroll PR. PMID: 19549119.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    320. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst. 2009 Jun 16; 101(12):878-87. Cooperberg MR, Broering JM, Carroll PR. PMID: 19509351.
      View in: PubMed   Mentions: 81     Fields:    Translation:Humans
    321. Management of localized prostate cancer in men over 65 years. Curr Opin Urol. 2009 May; 19(3):309-14. Cooperberg MR, Konety BR. PMID: 19357512.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    322. Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol. 2010 Apr; 57(4):622-9. Eisenberg ML, Davies BJ, Cooperberg MR, Cowan JE, Carroll PR. PMID: 19375843.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    323. Patients with primary hyperparathyroidism--why do some form stones? J Urol. 2009 May; 181(5):2141-5. Berger AD, Wu W, Eisner BH, Cooperberg MR, Duh QY, Stoller ML. PMID: 19296981.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    324. Are age-based criteria the best way to determine eligibility for prostate cancer screening? Ann Intern Med. 2009 Feb 03; 150(3):220-1; author reply 221-2. Konety BR, Cooperberg MR, Carroll PR. PMID: 19189916.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    325. Geographic distribution of urologists throughout the United States using a county level approach. J Urol. 2009 Feb; 181(2):760-5; discussion 765-6. Odisho AY, Fradet V, Cooperberg MR, Ahmad AE, Carroll PR. PMID: 19091334.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    326. Prostate cancer risk assessment: choosing the sharpest tool in the shed. Cancer. 2008 Dec 01; 113(11):3062-6. Cooperberg MR. PMID: 18855919.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    327. Health related quality of life in patients treated with multimodal therapy for prostate cancer. J Urol. 2008 Dec; 180(6):2415-22; discussion 2422. Wu AK, Cooperberg MR, Sadetsky N, Carroll PR. PMID: 18930279.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    328. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer. 2008 Jul 01; 113(1):78-83. Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. PMID: 18491376.
      View in: PubMed   Mentions: 119     Fields:    Translation:Humans
    329. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer. 2008 Jun 15; 112(12):2664-70. Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, Meng MV, Kane CJ, Perez N, Master VA, Carroll PR. PMID: 18433013.
      View in: PubMed   Mentions: 103     Fields:    Translation:HumansCTClinical Trials
    330. Decreasing size at diagnosis of stage 1 renal cell carcinoma: analysis from the National Cancer Data Base, 1993 to 2004. J Urol. 2008 Jun; 179(6):2131-5. Cooperberg MR, Mallin K, Ritchey J, Villalta JD, Carroll PR, Kane CJ. PMID: 18423754.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    331. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer. 2008 Apr 15; 112(8):1650-9. Dall'Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg L, Bailey DE, Wallace ME, Kantoff PW, Carroll PR. PMID: 18306379.
      View in: PubMed   Mentions: 87     Fields:    Translation:HumansPHPublic Health
    332. High-risk prostate cancer in the United States, 1990-2007. World J Urol. 2008 Jun; 26(3):211-8. Cooperberg MR, Cowan J, Broering JM, Carroll PR. PMID: 18369637.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    333. Oral calcium supplementation associated with decreased likelihood of nephrolithiasis prior to surgery for hyperparathyroidism. Int J Urol. 2007 Dec; 14(12):1113-5. Cooperberg MR, Duh QY, Stackhouse GB, Stoller ML. PMID: 18036056.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    334. Urinary citrate levels do not correlate with urinary pH in patients with urinary stone formation. Urology. 2007 Oct; 70(4):634-7. Whitson JM, Cooperberg MR, Stackhouse GB, Stoller ML. PMID: 17991528.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    335. Trends in regionalization of inpatient care for urological malignancies, 1988 to 2002. J Urol. 2007 Nov; 178(5):2103-8; discussion 2108. Cooperberg MR, Modak S, Konety BR. PMID: 17870128.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    336. Urethral reconstruction for traumatic posterior urethral disruption: outcomes of a 25-year experience. J Urol. 2007 Nov; 178(5):2006-10; discussion 2010. Cooperberg MR, McAninch JW, Alsikafi NF, Elliott SP. PMID: 17869302.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    337. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007 Sep; 178(3 Pt 2):S14-9. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. PMID: 17644125.
      View in: PubMed   Mentions: 129     Fields:    Translation:Humans
    338. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer. 2006 Nov 15; 107(10):2384-91. Cooperberg MR, Freedland SJ, Pasta DJ, Elkin EP, Presti JC, Amling CL, Terris MK, Aronson WJ, Kane CJ, Carroll PR. PMID: 17039503.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    339. Differences in clinical characteristics and disease-free survival for Latino, African American, and non-Latino white men with localized prostate cancer: data from CaPSURE. Cancer. 2006 Feb 15; 106(4):789-95. Latini DM, Elkin EP, Cooperberg MR, Sadetsky N, Duchane J, Carroll PR. PMID: 16400651.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    340. The changing face of prostate cancer. J Clin Oncol. 2005 Nov 10; 23(32):8146-51. Cooperberg MR, Moul JW, Carroll PR. PMID: 16278465.
      View in: PubMed   Mentions: 81     Fields:    Translation:Humans
    341. Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology. 2005 Nov; 66(5):1060-5. Bassett WW, Cooperberg MR, Sadetsky N, Silva S, DuChane J, Pasta DJ, Chan JM, Anast JW, Carroll PR, Kane CJ. PMID: 16286124.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    342. Who is the average patient presenting with prostate cancer? Urology. 2005 Nov; 66(5 Suppl):76-82. Greene KL, Cowan JE, Cooperberg MR, Meng MV, DuChane J, Carroll PR. PMID: 16194711.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    343. Variability in testis biopsy interpretation: implications for male infertility care in the era of intracytoplasmic sperm injection. Fertil Steril. 2005 Sep; 84(3):672-7. Cooperberg MR, Chi T, Jad A, Cha I, Turek PJ. PMID: 16169401.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    344. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005 Jun; 173(6):1938-42. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, Carroll PR. PMID: 15879786.
      View in: PubMed   Mentions: 149     Fields:    Translation:Humans
    345. Laparoscopic management of peripelvic renal cysts: University of California, San Francisco, experience and review of literature. Urology. 2005 May; 65(5):882-7. Camargo AH, Cooperberg MR, Ershoff BD, Rubenstein JN, Meng MV, Stoller ML. PMID: 15882716.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    346. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J Urol. 2005 Apr; 173(4):1126-31. Mitchell JA, Cooperberg MR, Elkin EP, Lubeck DP, Mehta SS, Kane CJ, Carroll PR. PMID: 15758720.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    347. The impact of obesity on health related quality of life before and after radical prostatectomy (data from CaPSURE). J Urol. 2005 Apr; 173(4):1132-8. Anast JW, Sadetsky N, Pasta DJ, Bassett WW, Latini D, DuChane J, Chan JM, Cooperberg MR, Carroll PR, Kane CJ. PMID: 15758721.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    348. Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE. J Urol. 2005 Mar; 173(3):732-6. Kane CJ, Bassett WW, Sadetsky N, Silva S, Wallace K, Pasta DJ, Cooperberg MR, Chan JM, Carroll PR. PMID: 15711258.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    349. Percutaneous neuromodulation. Urol Clin North Am. 2005 Feb; 32(1):71-8, vii. Cooperberg MR, Stoller ML. PMID: 15698879.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    350. Prostate cancer 2004: insights from national disease registries. Oncology (Williston Park). 2004 Sep; 18(10):1239-47; discussion 1248-50, 1256-8. Cooperberg MR, Park S, Carroll PR. PMID: 15526829.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    351. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from cancer of the prostate strategic urological research endeavor (capsure). J Urol. 2004 Jun; 171(6 Pt 1):2255-9. Greene KL, Meng MV, Elkin EP, Cooperberg MR, Pasta DJ, Kattan MW, Wallace K, Carroll PR. PMID: 15126797.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    352. Patterns of practice in the United States: insights from CaPSURE on prostate cancer management. Curr Urol Rep. 2004 Jun; 5(3):166-72. Cooperberg MR, Broering JM, Latini DM, Litwin MS, Wallace KL, Carroll PR. PMID: 15161564.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    353. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004 Jun 01; 22(11):2141-9. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. PMID: 15169800.
      View in: PubMed   Mentions: 141     Fields:    Translation:Humans
    354. Radical retropubic prostatectomy frustrated by prior laparoscopic mesh herniorrhaphy. Surgery. 2004 Apr; 135(4):452-3; discussion 454. Cooperberg MR, Downs TM, Carroll PR. PMID: 15041971.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    355. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol. 2004 Apr; 171(4):1393-401. Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, Carroll PR. PMID: 15017184.
      View in: PubMed   Mentions: 88     Fields:    Translation:Humans
    356. Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells. Cancer Res. 2004 Jan 15; 64(2):704-10. Liu B, Conrad F, Cooperberg MR, Kirpotin DB, Marks JD. PMID: 14744788.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    357. The evolving role of androgen deprivation therapy in the management of prostate cancer. Minerva Urol Nefrol. 2003 Dec; 55(4):219-38. Cooperberg MR, Small EJ, D'Amico A, Carroll PR. PMID: 14765015.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    358. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol. 2003 Dec; 170(6 Pt 2):S21-5; discussion S26-7. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR. PMID: 14610406.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansPHPublic Health
    359. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol. 2003 Nov; 170(5):1804-7. Harlan SR, Cooperberg MR, Elkin E, Lubeck DP, Meng M, Mehta SS, Carroll PR. PMID: 14532780.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    360. Sociodemographic and clinical risk characteristics of patients with prostate cancer within the Veterans Affairs health care system: data from CaPSURE. J Urol. 2003 Sep; 170(3):905-8. Cooperberg M, Lubeck DP, Penson D, Mehta SS, Carroll PR, Kane CJ. PMID: 12913727.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    361. Health related quality of life significance of single pad urinary incontinence following radical prostatectomy. J Urol. 2003 Aug; 170(2 Pt 1):512-5. Cooperberg MR, Master VA, Carroll PR. PMID: 12853811.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    362. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst. 2003 Jul 02; 95(13):981-9. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. PMID: 12837834.
      View in: PubMed   Mentions: 96     Fields:    Translation:Humans
    363. How potent is potent? Evaluation of sexual function and bother in men who report potency after treatment for prostate cancer: data from CaPSURE. Urology. 2003 Jan; 61(1):190-6. Cooperberg MR, Koppie TM, Lubeck DP, Ye J, Grossfeld GD, Mehta SS, Carroll PR. PMID: 12559294.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    364. Contemporary trends in imaging test utilization for prostate cancer staging: data from the cancer of the prostate strategic urologic research endeavor. J Urol. 2002 Aug; 168(2):491-5. Cooperberg MR, Lubeck DP, Grossfeld GD, Mehta SS, Carroll PR. PMID: 12131295.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    365. Stroke in surgery of the thoracic aorta: incidence, impact, etiology, and prevention. J Thorac Cardiovasc Surg. 2001 Nov; 122(5):935-45. Goldstein LJ, Davies RR, Rizzo JA, Davila JJ, Cooperberg MR, Shaw RK, Kopf GS, Elefteriades JA. PMID: 11689799.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    366. Ki-1 anaplastic large-cell lymphoma occurring at the site of ileocolonic anastomosis in a patient treated surgically for colonic adenocarcinoma: case report and review of the literature. Ann Diagn Pathol. 2001 Jun; 5(3):162-7. Cooperberg MR, Fiedler PN. PMID: 11436170.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    367. Cystic pelvic pathology presenting as falsely elevated post-void residual urine measured by portable ultrasound bladder scanning: report of 3 cases and review of the literature. Urology. 2000 Apr; 55(4):590. Cooperberg MR, Chambers SK, Rutherford TJ, Foster HE. PMID: 10754180.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    368. Methods for Chemoprotection and Chemosensitization : MDR-1 For Chemoprotection Using Retroviruses to Modify Hematopoietic Cells and Cytosine Deaminase for Chemosensitization Using Adenoviral Vectors to Modify Epithelian Neoplastic Cells. Methods Mol Med. 2000; 35:609-16. Shrimdkandada S, Fu SQ, Yin LH, Guo XY, Nanakorn T, Peng XY, Dizon D, Lin D, Cooperberg M, Won JH, Deisseroth A. PMID: 21390834.
      View in: PubMed   Mentions:    Fields:    
    369. Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologous transplantation. Blood. 1998 Jul 15; 92(2):672-82. Garcia-Sanchez F, Pizzorno G, Fu SQ, Nanakorn T, Krause DS, Liang J, Adams E, Leffert JJ, Yin LH, Cooperberg MR, Hanania E, Wang WL, Won JH, Peng XY, Cote R, Brown R, Burtness B, Giles R, Crystal R, Deisseroth AB. PMID: 9657770.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    Matthew's Networks
    Concepts (610)
    Derived automatically from this person's publications.
    _
    Co-Authors (95)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _